

September 8, 2023

To,

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400051

Stock Code: VAISHALI

Sub: Revised Annual General Meeting Notice. Annual Report

Dear Sir/ Ma'am,

The 16th Annual General Meeting ("AGM") of the Company will be held on Friday, September 29, 2023 at 12:00 Noon IST through Video Conferencing / Other Audio Visual Means.

The Company have uploaded Annual Report for the financial year 2022-2023 on September 07, 2023 with stock exchange, wherein a typographic error in the Annual Report under notice section in the Special business have come to our notice.

The Actual Remuneration of Mr. Atul Arvind Vasani is Rs. 54,00,000/- (Rupees Fifty-four Lakhs only) and Mrs. Jagruti Atul Vasani is Rs. 1200000/- (Rupees Twelve Lakhs only) but under explanatory statement accompanying the notice convening AGM dated September 29, 2023 it is erroneously mentioned for Mr. Atul Arvind Vasani as Rs. 540,000/- /- (Rupees Five Lakhs Forty Thousand only) and for Mrs. Jagruti Atul Vasani is Rs. 120,000/- (Rupees One Lakh Twenty Thousand only).

We intend to rectify the aforesaid error and hence, have attached revised Annual Report for the financial year 2022-2023.

Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Annual Report of the Company along with the revised notice of AGM for the financial year 2022-23 which is being sent to the Members, who have registered their e-mail addresses with the Company/ Depositories, through electronic mode.

The Integrated Revised Annual Report containing the Notice is also uploaded on the Company's website www.vaishalipharma.com.

Kindly take the above notice on record.

Thanking you.

Yours faithfully

For Vaishali Pharma Limited


Vishwa Mekhia

Company Secretary & Compliance Officer

ENCL: Revised Annual Report for the financial year 2022-2023



Vaishali Pharma Ltd.
Healthy Healthcare Solutions...!



“

ANNUAL REPORT

2022 – 23

”

PRODUCT PORTFOLIO



GLOBAL CERTIFICATIONS

Company Certifications



NSE - MAIN BOARD

Formulation Certifications



CAMEROON



CAMBODIA



COSTA RICA



DR CONGO



ETHIOPIA



KENYA



MADAGASCAR



MYANMAR



NICARAGUA



UAE



RUSSIA



TAJIKISTAN



SRI-LANKA



YEMEN



ZIMBABWE



KAZAKSTAN



NIGERIA



MOROCCO



OMAN



Lesotho




TURKMENUSTAN



NDA UGANDA


ACHIEVEMENT AND AWARDS



One Star Export House

Prestigious Rising
Brands of Asia 2018-19

Surgical Certifications



ISO 9001 : 2015



CE



ISO 13485 : 2016

KEY STRENGTHS



DIVERSIFIED PRODUCT
RANGE



QUALITY ASSURANCE
& HIGH QUALITY SERVICE
SUPPORT



GLOBAL PRESENCE
&
COMPETITIVE RATES



SCALABLE BUSINESS
MODEL



EXPERIENCED PROMOTERS
&
MANAGEMENT
TEAM

**Key
Strengths**

- Offering range from Formulations, Bulk Drugs, APIs, Veterinary Products, Surgical and Neutraceutical Products Marketing approximately 400 products in Domestic and has product portfolio of more than 1,000 products for overseas market.
- Caters to Asian, African, CIS and Latin American companies Applied for 200 registrations in 35+ countries 250+ approvals.
- Accredited & Certified by International board & Organisations.
- Chairman Mr. Atul Vasani engaged in Pharmaceutical business for more than 3 decades. Well equipped dedicated Personnel enable to take advantage of both current and future market opportunities.
- Customer Centric and Order driven Business model Optimum utilisation of resources assuring quality supply enable to achieve economies of scale Development of new market and products by exploring customer needs, marketing expertise by maintaining quality output.

BUSINESS MODEL


Vision

- To be a well recognized Indian MNC in The Pharmaceutical & healthcare industry.

Mission

- To contribute substantially towards well - being and health of the society by providing high quality products and services.

● ● ● ● ● ● EXCLUSIVE BRANDING ● ● ● ● ● ●



COMPANY OVERVIEW

Among Fastest Growing Companies in pharmaceutical industry accross globe

- Established in 1989
- Incorporated as Private limited company in 2008
- Converted into Public Limited Company in 2017
- Listed on NSE - Emerge (SME) in 2017
- Achieved STAR EXPORT HOUSE Status by Govt. of India
- Awarded as Prestigious Rising Brands of Asia 2018-19 by Herald Global
- Migrated to NSE - Mainboard (EQ) in 2020

Diversified Product Portfolio

- Present dosage forms comprises of: Tablets, Capsules, Oral Liquids , Injections (Dry & Liquid), Dry Syrups in Human / Veterinary; Surgical devices,Oncology, Herbal and Nutraceutical products & API's

Experienced Sales & Distribution

- Well established sales & Distribution management system.
- Efficient execution & Logistic system backed with FlexiERP software for zero defect quality management & Distribution system.
- Strong team of Sales & Marketing Professionals having presence in PAN India.

Offices

- Corporate Office : Headquarters located amidst economic hub of India, Mumbai
- Overseas Regional Office :Vietnam
- Warehouse at Bhiwandi, Maharashtra


Offices

- ISO 9001 : 2015 for Quality Management System from CPG
- ISO 9001 : 2015 from Deutsche Accreditation Board, Germany



BUSINESS STRUCTURE

Vaishali Pharma



CORPORATE INFORMATION**BOARD OF DIRECTORS**

Mr. Atul Vasani	Chairman & Managing Director
Mrs. Jagruti Vasani	Whole Time Director
Mr. Dewansh Vasani	Executive Director
Mr. Ashvin Ganatra	Independent Director
Mr. Manish Ved	Independent Director
Mr. Pratik Jakhelia	Independent Director

KEY MANAGERIAL PERSONNEL

Mr. Hemanth Pathak	Chief Executive Officer
Mr. Ratnesh Singh	Chief Financial Officer
Ms. Vishwa Mekhia	Company Secretary & Compliance Officer

AUDITORS

M/s. Raman S. Shah & Associates	Statutory Auditors
M/s. R. U. Kamath & Co.	Internal Auditor
M/s. Disha & Associates	Secretarial Auditor

BOARD COMMITTEES**AUDIT COMMITTEE**

Mr. Manish Ved	Chairman
Mr. Pratik Jakhelia	Member
Mr. Ashvin Ganatra	Member
Mr. Atul Vasani	Member

NOMINATION AND REMUNERATION COMMITTEE

Mr. Manish Ved	Chairman
Mr. Pratik Jakhelia	Member
Mr. Ashvin Ganatra	Member

STAKEHOLDER RELATIONSHIP COMMITTEE

Mr. Manish Ved	Chairman
Mr. Pratik Jakhelia	Member
Mr. Ashvin Ganatra	Member
Mr. Dewansh Vasani	Member

REGISTERED OFFICE

L52310MH2008PLC181632
Vaishali Pharma Limited
 706 to 709, 7th Floor, Aravali Business Center,
 R. C. Patel Road, Off Sodawala Lane, Borivali
 (West),
 Mumbai – 400092. Maharashtra, India.
 Tele No. – 022 42171819
 Email - investor@vaishalipharma.com
 Website - www.vaishalipharma.com

Sr. No.	Content	Page No.
1	Introduction	2
2.	Chairman's Message	3
3.	Notice of Annual General Meeting	4
4.	Directors Report with Annexures	15
5.	Auditors Report	56
6.	Financial Statement	68

REGISTRAR AND TRANSFER AGENT**Bigshare Services Private Limited**

Office No S6-2, 6th Floor, Pinnacle Business Park,
 Next to Ahura Centre, Mahakali Caves Road,
 Andheri (East), Mumbai – 400093
 E-mail: info@bigshareonline.com
 Tel No. : +91 22 6263 8222
 Fax No. : +91 226263 8299



INTRODUCTION

Welcome to Vaishali Pharma Limited, a steadfast participant in the journey of transformation, relentlessly expanding avenues of growth while enhancing operational efficiency. Our philosophy holds that "Quality is an ongoing process of building and sustaining relationships," a principle that propels our dedication to delivering excellence. Our robust commitment to quality products is fortified by profound industry expertise, a skilled team of professionals, and state-of-the-art infrastructure. These elements converge to foster mutually advantageous partnerships for all stakeholders involved.

With a legacy dating back to 1989, Vaishali Pharma Limited has solidified its reputation as a globally trusted brand synonymous with top-tier products, embraced by enterprises across the world. We stand tall among the leading purveyors of pharmaceutical offerings, encompassing Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary Supplements, Herbal & Nutraceutical Products. Our well-established brand is synonymous with unparalleled quality, endorsed by a diverse clientele spanning the globe. Boasting an extensive portfolio of over 250 formulation brands marketed across numerous nations, each dossier meticulously crafted in CTD format alongside its corresponding bioequivalence data. Our robust pipeline comprises around 250 Dossiers, a testament to our commitment to innovation. The bedrock of our success lies in strategic partnerships with WHO-GMP compliant manufacturing facilities, underpinned by our exceptional rapport with clients.

Our unwavering commitment to product quality is fortified by extensive industry acumen, a team of adept professionals, and cutting-edge infrastructure. This synergy facilitates the cultivation of mutually advantageous relationships with every client.

Our allegiance to impeccable quality standards is not coincidental but rather a habitual practice. Fueled by an unyielding aspiration to be at the pinnacle, we take immense pride in our endeavors, striving to deliver flawlessness with every product. You can confidently rely on us for uncompromising pharmaceutical and healthcare solutions.

Swift adaptation to the ever-evolving market dynamics has propelled us to become one of the pharmaceutical industry's fastest-growing entities, exporting healthcare solutions from India. Our headquarters are strategically nestled in Mumbai, the pulsating economic nucleus of India.

CHAIRMAN'S MESSAGE

Esteemed Shareholders,

As we reflect on the past year and look forward to the challenges and opportunities ahead, I am honored to share with you the remarkable journey of Vaishali Pharma Limited. In an ever-evolving landscape, our commitment to excellence remains unwavering, and I am pleased to present our company's achievements in the fiscal year 2022-23.

The global economic environment has been marked by diverse uncertainties, posing both trials and prospects. In this dynamic scenario, Vaishali Pharma Limited has demonstrated its resilience and adaptability, emerging as a beacon of stability in the pharmaceutical sector.

The pharmaceutical industry, a cornerstone of global health and well-being, stands at a pivotal juncture. Our commitment to ensuring universal access to quality healthcare continues to guide our actions. The pursuit of this noble objective propels us to innovate, collaborate, and forge partnerships that resonate with our values and aspirations.

Our legacy, dating back to 1989, is a testament to our dedication and the trust placed in us by our stakeholders. Over the years, we have transformed challenges into stepping stones for growth, fostering enduring relationships with customers, partners, and communities we serve.

In the pursuit of operational excellence, we have fortified our capabilities across Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary Supplements, Herbal & Nutraceutical Products. Our diversified portfolio and strategic collaborations reflect our commitment to delivering quality and value across geographies.

As we extend our global footprint, our presence spans across diverse nations, from Russia to UAE, from Madagascar to Palestine. This expansive reach underscores our commitment to shaping the healthcare landscape on a global scale.

While the path forward might be characterized by uncertainty, we are confident in our ability to navigate these challenges with integrity, innovation, and a dedication to our core values. Our steadfast team, state-of-the-art infrastructure, and unwavering commitment to quality position us to not only withstand the headwinds but also to emerge stronger and more resilient.

The road ahead demands vigilance, agility, and a deep understanding of market dynamics. We are poised to seize emerging opportunities and diversify our capabilities to ensure sustained growth. Our strong financial foundation, synergistic partnerships, and unwavering customer focus empower us to create value for our shareholders and contribute meaningfully to society.

I extend my heartfelt gratitude to our valued shareholders, esteemed customers, dedicated employees, and steadfast partners for their continued support. Your trust and commitment drive us to constantly strive for excellence, and we eagerly anticipate the journey ahead.

Thanking You,
Yours sincerely,

Atul Vasani
Chairman & Managing Director
DIN: 02107085



NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that 16th Annual General Meeting of the Members of **Vaishali Pharma Limited** (“the Company”) will be held on Friday, September 29, 2023 at 12:00 Noon through Video Conference (VC) / Other Audio Visual Means (OAVM), to transact the following business. The venue of the meeting shall be deemed to be the Registered Office of the Company at 706 to 709, 7th Floor, Aravali Business Center, R. C. Patel Road, off. Sodawala Lane, Borivali (West), Mumbai – 400 092.

ORDINARY BUSINESS:

1. To receive consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2023 together with the Reports of the Board of Directors and the Auditors thereon;
2. To consider appointment of a Director, Mrs. Jagruti Vasani (DIN: 02107094), liable to retire by rotation, and being eligible, offers herself for re-appointment.

SPECIAL BUSINESS:

3. To approve the aggregate annual remuneration payable to the Promoter - Executive Directors /Members of the Promoter Group exceeding 5% of the Net Profits of the Company calculated as per Section 198 of the Companies Act, 2013, and in this regard to pass, the following resolution as a Special Resolution:

“**RESOLVED THAT** pursuant to sub regulation 6 (e) of Regulation 17 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, approval be and is hereby accorded to pay the aggregate annual remuneration to the existing Promoters Executive Directors/Members of the Promoter Group exceeding 5 per cent of the Net Profits of the Company, calculated as per Section 198 of the Companies Act, 2013, for the remaining tenure.

RESOLVED FURTHER THAT any Director and/or Company Secretary of the Company be and is hereby severally authorized to do all such acts and take such steps as may be necessary, proper or expedient to give effect to this resolution.”

Date: September 05, 2023
Place: Mumbai

By Order of the Board of Directors
For Vaishali Pharma Limited
Sd/-
Vishwa Mekhia
Company Secretary & Compliance Officer

Notes:-

1. Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (the Act) relating to the special businesses to be transacted at the 16th Annual General Meeting (AGM) as set out in the Notice, is annexed hereto.
2. The Ministry of Corporate Affairs ("MCA"), vide its General circular nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and 10/2022 dated December 28, 2022 (collectively "MCA Circulars") and Securities and Exchange Board of India ("SEBI") vide its circular nos. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023 (collectively "SEBI Circulars"), have permitted companies to conduct AGM through VC or other audio visual means, subject to compliance of various conditions mentioned therein. In compliance with the aforesaid MCA and SEBI Circulars, applicable provisions of the Companies Act, 2013 and rules made thereunder, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), the 16th AGM of the Company is being convened and conducted through VC. The registered office of the Company shall be deemed to be the venue for the AGM.
3. To take note of the specific instructions given to the Shareholders:

The Company sought Members approval for issue of 2500000 (Twenty-Five Lakhs) convertible Share Warrants, on preferential basis at an issue price of Rs. 121.82/- (Rupees One Hundred Twenty One Rupees and Eighty Two Paise Only) per warrant. For the same, the Company received "In-Principle approval" of the National Stock Exchange of India Limited (vide its letter reference no. NSE/LIST /33669) dated January 24, 2023.

We have disclosed the status of promoter and non-promoter, In point xv and xviii of Explanatory Statement to the Notice of EGM, i.e. the current and proposed status of the allottee(s) post the preferential issues namely, promoter or non-promoter.

SR. NO	NAME AND DETAILS OF PROPOSED ALLOTTEES	ULTIMATE BENEFICIAL OWNERS (IF APPLICABLE)	CATEGORY (PROMOTER / NON PROMOTER)	PROPOSED NO OF WARRANTS IN THE COMPANY TO BE ALLOTTED	PRE-ISSUE SHAREHOLDING		POST-ISSUE SHAREHOLDING**	
					No of Shares	%	No of Shares	%
1	Atul Arvind Vasani	NA	Promoter/ Director	852000	2262023	21.45%	3114023	23.87%
2	Jagruti Atul Vasani	NA	Promoter/ Director	200000	479992	4.55%	679992	5.21%
3	Dewansh Ajay Vasani	NA	Promoter Group / Director	100000	1	0.00%	100001	0.77%
4	Priyanka Atul Vasani	NA	Promoter Group	100000	1	0.00%	100001	0.77%
5	Kevin Atul Vasani	NA	Promoter Group	50000	1	0.00%	50001	0.38%
6	Sandeep Gunvantra Oza	NA	Non-Promoter	100000	13000	0.12%	113000	0.87%
7	Archana Sandeep Oza	NA	Non-Promoter	75000	10000	0.09%	85000	0.65%
8	Kirit Chimanlal Tolia	NA	Non-Promoter	100000	63750	0.60%	163750	1.26%
9	Nina Dilip Parikh	NA	Non-Promoter	7500	0	0.00%	7500	0.06%
10	Parikh Hariyali Vishal	NA	Non-Promoter	7500	0	0.00%	7500	0.06%
11	Vishal D Parikh	NA	Non-Promoter	8000	0	0.00%	8000	0.06%
12	Kusum Dinesh Sagar	NA	Non-Promoter	25000	0	0.00%	25000	0.19%
13	Sonal Sanjay Mirani	NA	Non-Promoter	200000	4671	0.04%	204671	1.57%
14	Ketan Chhaganlal Patel	NA	Non-Promoter	100000	0	0.00%	100000	0.77%



SR. NO	NAME AND DETAILS OF PROPOSED ALLOTTEES	ULTIMATE BENEFICIAL OWNERS (IF APPLICABLE)	CATEGORY (PROMOTER / NON PROMOTER)	PROPOSED NO OF WARRANTS IN THE COMPANY TO BE ALLOTTED	PRE-ISSUE SHAREHOLDING		POST-ISSUE SHAREHOLDING**	
					No of Shares	%	No of Shares	%
15	Sanjay Sureshchandra Shah	NA	Non-Promoter	100000	0	0.00%	100000	0.77%
16	Aashna Umesh Hegde	NA	Non-Promoter	100000	0	0.00%	100000	0.77%
17	Rumit Bharatbhai Gopani	NA	Non-Promoter	50000	955	0.01%	50955	0.39%
18	Rajvi Krupal Shah	NA	Non-Promoter	25000	0	0.00%	25000	0.19%
19	Sagar Deepak Kothari	NA	Non-Promoter	50000	6100	0.06%	56100	0.43%
20	Sanjay Girdharlal Mirani	NA	Non-Promoter	200000	0	0.00%	200000	1.53%
21	Bhavik Dolatrai Mehta	NA	Non-Promoter	10000	0	0.00%	10000	0.08%
22	Radha Bhavik Mehta	NA	Non-Promoter	10000	0	0.00%	10000	0.08%
23	Roopa Dolatray Mehta	NA	Non-Promoter	10000	0	0.00%	10000	0.08%
24	Sheetal Parag Mehta	NA	Non-Promoter	10000	0	0.00%	10000	0.08%
25	Parag Dolatray Mehta	NA	Non-Promoter	10000	0	0.00%	10000	0.08%
TOTAL				25,00,000				

- The Company has enabled the Members to participate at the 16th AGM through VC facility. The instructions for participation by Members are given in the subsequent pages. Participation at the AGM through VC shall be allowed on a first-come-first-served basis.
- The relevant details, pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India, in respect of Director seeking appointment/ re-appointment at this AGM is annexed.
- Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip including Route Map are not annexed to this Notice.
- Institutional / Corporate Shareholders (i.e. other than individuals / HUF, NRI, etc.) are required to send a scanned copy (PDF/JPG Format) of its Board or governing body Resolution/Authorization etc., authorizing its representative to attend the AGM through VC / OAVM on its behalf and to vote through remote e-voting. The said Resolution/Authorization shall be sent to the Scrutinizer by email through its registered email address to investor@vaishalipharma.com with a copy marked to evoting@nsdl.co.in.
- The Register of Members and Share Transfer Books of the Company will remain closed from Saturday, September 23, 2023 to Friday, September 29, 2023 (both days inclusive).
- In accordance with, the General Circular No. 20/2020 dated 5th May, 2020 issued by MCA and Circular No. SEBI/HO/CFD/ CMD1/CIR/P/2020/79 dated 12th May, 2020 and Circular No SEBI/HO/CFD/PoD-2/P/CIR/2023/4 date 5th January 2023 issued by SEBI, owing to the difficulties involved in dispatching of

physical copies of the financial statements (including Report of Board of Directors, Auditor's report or other documents required to be attached therewith), such statements including the Notice of AGM are being sent in electronic mode to Members whose e-mail address is registered with the Company or the Depository Participant(s).

10. Members holding shares in physical mode and who have not updated their email addresses with the Company are requested to update their email addresses by writing to the Company at investor@vaishalipharma.com along with the copy of the signed request letter mentioning the name and address of the Member, self-attested copy of the PAN card, and self-attested copy of any document (eg: Driving License, Election Identity Card, Passport) in support of the address of the Member. Members holding shares in dematerialised mode are requested to register / update their email addresses with the relevant Depository Participants. In case of any queries / difficulties in registering the e-mail address, Members may write to investor@vaishalipharma.com.
11. As per Regulation 40 of SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from, April 1, 2019, except in case of request received for transmission or transposition of securities. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents, Bigshare Services Private Limited for assistance in this regard. Members may also refer Company's website www.vaishalipharma.com for any queries.
12. All the documents referred to in the accompanying Notice and Explanatory Statements, shall be available for inspection through electronic mode, basis the request being sent on investor@vaishalipharma.com.
13. During the AGM, the Register of Directors and Key Managerial Personnel and their Shareholding maintained under Section 170 of the Act, the Register of Contracts or arrangements in which Directors are interested under Section 189 of the Act and other statutory documents shall be available for inspection upon login at NSDL e-voting system at <https://www.evoting.nsdl.com>.
14. In terms of Section 152 of the Act, Mrs. Jagruti Atul Vasani (DIN: 02107094), is liable to retire by rotation at this Annual General Meeting and being eligible, offers herself for re-appointment.
15. To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their DPs in case the shares are held by them in electronic form and with Bigshare Services Private Limited in case the shares are held by them in physical form.
16. Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their DPs in case the shares are held by them in electronic form and to Bigshare Services Private Limited in case the shares are held by them in physical form.
17. Members are requested to submit the said details to their DP in case the shares are held by them in electronic form and to Bigshare Services Private Limited in case the shares are held in physical form.
18. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.
19. Members seeking any information with regard to the accounts or any matter to be placed at the AGM, are requested to write to the Company on or before September 12, 2023 through email on investor@vaishalipharma.com. The same will be replied by the Company suitably.
20. Members may note that the Notice and Annual Report 2022 - 23 will also be available on the Company's website www.vaishalipharma.com, website of the Stock Exchange i.e. National Stock Exchange of India Limited at www.nseindia.com, and on the website of NSDL at <https://www.evoting.nsdl.com>.



21. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
22. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as venue voting on the date of the AGM will be provided by NSDL.
23. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 08, 2020 and MCA Circular No. 17/2020 dated April 13, 2020, MCA Circular No. 20/2020 dated May 05, 2020 and MCA Circular No. 2/ dated January 13, 2021.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on Tuesday, September 26, 2023 9:00 A.M. and ends on Thursday, September 28, 2023 5:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. Saturday, September 23, 2023, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Saturday, September 23, 2023.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:





Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the “ Beneficial Owner ” icon under “ Login ” which is available under ‘ IDeAS ’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “ Access to e-Voting ” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service

	<p>provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>2. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</p> <p>3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>4. Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.</p> <div style="text-align: center;"> <p>NSDL Mobile App is available on</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>App Store</p> </div> <div style="text-align: center;">  <p>Google Play</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;">   </div> </div>
Individual Shareholders holding securities in demat mode with CDSL	<p>1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password.</p> <p>2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers’ website directly.</p>



	<p>3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.</p> <p>4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at 022 - 4886 7000 and 022 - 2499 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.

2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****
b) For Members who hold shares in demat account with CDSL	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the ‘initial password’ which was communicated to you. Once you retrieve your ‘initial password’, you need to enter the ‘initial password’ and the system will force you to change your password.
 - c) How to retrieve your ‘initial password’?
 - (i) If your email ID is registered in your demat account or with the company, your ‘initial password’ is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your ‘User ID’ and your ‘initial password’.
 - (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.
6. If you are unable to retrieve or have not received the “ Initial password” or have forgotten your password:
 - a) Click on “Forgot User Details/Password?”(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password?” (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.



8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on “VC/OAVM” link placed under “Join Meeting”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to investor@gmail.com with a copy marked to evoting@nsdl.co.in. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details/Password?” or “Physical User Reset Password?” option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 and 022 - 2499 7000 or send a request to Pallavi Mahtre Senior Manager at evoting@nsdl.co.in.

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to investor@vaishalipharma.com
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to investor@vaishalipharma.com. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**

3. Alternatively shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of “VC/OAVM” placed under “Join meeting” menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at investor@vaishalipharma.com. The same will be replied by the company suitably.



EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

Item No. 3:

Securities and Exchange Board of India vide its notification dated 9th May 2018 amended sub-regulation 6, of Regulation 17 of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) (Amendment) Regulations, 2018 by inserting new clause (e).

As per the amendment, if the aggregate annual remuneration payable to more than one Executive Director who belongs to the Promoter or is a Member of the Promoter Group, exceeds 5% of the net profits of the Company calculated as per Section 198 of the Companies Act, 2013 then approval of the Shareholders by way of Special Resolution is required. Such approval of the Shareholders under this provision shall be valid only till the expiry of the term of such Director.

The Company sought Members approval at:

(₹ in Lakhs)							
Meeting	Date of meeting	Appointment / Re-appointment	Name of Directors	Designation	Remuneration	Revised Remuneration	Tenure
15 th Annual General Meeting	September 30, 2022	Re-appointment	Mr. Atul Arvind Vasani	Managing Director	54.00	66.00	3 Years
15 th Annual General Meeting	September 30, 2022	Re-appointment	Mrs. Jagruti Atul Vasani	Whole-Time Director	12.00	16.80	3 Years
8 th Extra Ordinary General Meeting	August 05, 2021	Change in Designation From Non-Executive Director to Executive Director	Mr. Dewansh Ajay Vasani	Executive Director	12.00	-	-

As on March 31, 2023, 5% of the Net Profit calculated as per Section 198 of the Companies Act, 2013 comes to Rs. 47.93 Lakhs. Since, the aggregate annual remuneration payable to Executive Directors i.e. Mr. Atul Arvind Vasani, Managing Director, Mrs. Jagruti Atul Vasani, Whole-time Director and Mr. Dewansh Ajay Vasani, Executive Director; comes to Rs. 78.00 Lakh which exceeds 5% of the net profits of the Company calculated as per Section 198 of the Companies Act, 2013, it is necessary to obtain approval of the Members.

In view of the above, the Board recommends the Special Resolution at item no.3 as set in the accompanying notice for the approval of Members.

Except Mr. Atul Arvind Vasani, Mrs. Jagruti Atul Vasani and Mr. Dewansh Ajay Vasani, none of Directors/Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested in this resolution.

Date: September 05, 2023
Place: Mumbai

By Order of the Board of Directors
For Vaishali Pharma Limited
Sd/-
Vishwa Mekhia
Company Secretary & Compliance Officer

THE BOARD'S REPORT

To,
The Members

Vaishali Pharma Limited,

The Board of Directors of your Company take great pleasure in presenting the 16th Annual Report on the business and operations of the Company together with the Audited Financial Statements for the year ended March 31, 2023.

1. FINANCIAL RESULTS

The financial performance of the Company for the year ended March 31, 2023 is summarized below:

Particulars	(₹ in Lakhs)	
	Current year	Previous Year
	2022-2023	2021-2022
Income from Business Operations	6,966.28	7,582.08
Other Income	222.87	178.81
Total Income	7,189.15	7,760.89
Less: Expenses	6,304.62	7,188.06
Profit/(Loss) Before Tax	884.53	572.83
Less: Current Tax	215.71	145.48
Less: Adjustment of prior periods tax	8.10	26.81
Less: Deferred Tax (credit)/charge	0.43	(1.82)
Net Profit/(Loss) After Tax	660.29	402.35
Other Comprehensive Income/(Loss)	3.89	1.65
Total Comprehensive Income for the year	664.18	404.00

* Figures have been regrouped and reclassified, wherever required

2. FINANCIAL PERFORMANCE

During the year under review, total revenue earned by the Company was Rs. 7,189.15 Lakhs as compared to Rs. 7,760.89 Lakhs in previous year. The expenditure incurred during the year was Rs. 6,304.62 Lakhs as against the amount of Rs. 7,188.06 Lakhs during the previous year. The Company recorded a Net Profit after tax of Rs. 660.29 Lakhs as compared to the previous year of Rs. 402.35 Lakhs and it recorded increase by 64.12%. Your Directors are optimistic of future growth.

3. NATURE OF BUSINESS

The Company is into pharmaceutical business, mainly dealing in Active Pharmaceutical Ingredient, pharmaceutical formulations, surgical products, veterinary supplements operating in domestic and export markets.

The success of the Company depends significantly on ability to commercialize new pharmaceutical products in India and across various markets around the world.

4. DIVIDEND

Your Company is committed towards enhancing shareholder value for its investors. The Company has considered it prudent not to recommend the dividend for F.Y. 2022 - 2023 in order to maintain its liquidity position.

5. LISTING OF EQUITY SHARES

The equity shares of the Company are listed on the trading platform of National Stock Exchange of India Limited (NSE), a recognized stock exchange having nationwide trading terminal.



6. TRANSFER TO RESERVES

The Company has not transferred any amount to the reserves during the year ended March 31, 2023.

7. DEPOSITS

The Company has not accepted any deposits from public and as such no amount on account of principal or interest on deposits from public was outstanding as on March 31, 2023 in terms of Section 76 of the Companies Act, 2013.

8. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the Notes to the Financial Statements.

9. CHANGE IN THE NATURE OF BUSINESS

There has been no change in the nature of business during the year under review.

10. INTERNAL FINANCIAL CONTROLS:

The Company has well placed, proper and adequate internal financial control system that commensurate with the size, scale and complexity of its operations. The Company has in place a mechanism to identify, assess, monitor and mitigate various risks to key business objectives. Major risks identified by the business and functions are systematically addressed through mitigation action on continuing basis. These are routinely tested by Internal Auditors. The Audit observations on internal financial controls are periodically reported to the Audit Committee.

11. SHARE CAPITAL

During the year under review, the Company vide Members approval dated 5th August 2022 increased its Authorized share capital from existing Rs.11,00,00,000/- (Rupees Eleven Crores only) divided into (One Crore Ten Lakhs) equity shares of face value of Rs. 10/- each to Rs. 22,00,00,000/- (Rupees Twenty Two Crores only) divided into 2,20,00,000 (Two Crores Twenty Lakh) equity shares of face value of Rs. 10/- each.

The Equity paid up share capital of the Company stands at Rs.10,54,62,130 (Rupees Ten Crore Fifty Four Lakh Sixty Two Thousand One Hundred Thirty only) divided into 1,05,46,213 (One Crore Five Lakh Forty Six Thousand Two Hundred Thirteen) equity shares of Rs. 10/- each.

Apart from the above, there is no change in Share Capital of the Company during the year.

Further, during the year under review, the Company sought Members approval for issue of 2500000 (Twenty-Five Lakhs) convertible Share Warrants, on preferential basis at an issue price of Rs. 121.82/- (Rupees One Hundred Twenty One Rupees and Eighty Two Paise Only) per warrant. For the same, the Company received "In-Principle approval" of the National Stock Exchange of India Limited (vide its letter reference no. NSE/LIST /33669) dated January 24, 2023.

Furthermore, the Board allotted 2500000 (Twenty-Five Lakhs) convertible Share Warrants on February 07, 2023 to the allottees.

12. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There is no material change and commitment affecting the financial position of the Company that have occurred after closure of the financial year of the Company to which the financial statements relate and the date of the report.

13. RELATED PARTY TRANSACTIONS

During the period under review, the transactions entered into with related parties during the financial year were on arm's length pricing basis and in the ordinary course of business and do not attract the provisions of Section 188 of the Act. There were no materially significant transactions with related parties during the financial year which were in conflict with the interest of the Company. The particulars of contracts or arrangements with related parties referred to in Section 188(1) and applicable rules of the Companies Act, is disclosed in Form AOC-2 as shown in ANNEXURE – A.

All Related Party Transactions are periodically placed before the Audit Committee and also before the Board for approval. Prior omnibus approval of the Audit Committee is obtained for the transactions which are of a foreseeable and repetitive nature. The policy on Related Party Transactions as approved by the Board is available on website of the Company visa: <https://www.vaishalipharma.com/investors/company-policy>.

14. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES:

The Company does not have any Subsidiary, Joint Venture or Associate Company.

15. DIRECTORS RESPONSIBILITY STATEMENT:

Pursuant to Section 134 of the Companies Act, 2013, with respect to Directors' Responsibility Statement, it is hereby confirmed that:

- a) In the preparation of the annual accounts for the year ended March 31, 2023, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- b) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on March 31, 2023 and of the profit and loss of the Company for that period ended on that date;
- c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) The Directors had prepared the annual accounts on a going concern basis; and
- e) The Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.
- f) The Directors have devised proper system to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

16. DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. BOARD OF DIRECTORS

The Board of Directors of the Company comprise of 6 (Six) Directors with combination of 3 (Three) Independent Directors and 3 (Three) Executive Directors as on March 31, 2023.

The composition of the Board of Directors is as under:

1.	Mr. Atul Arvind Vasani	Chairman & Managing Director
2.	Mrs. Jagruti Atul Vasani	Whole Time Director
3.	Mr. Dewansh Ajay Vasani	Executive Director
4.	Mr. Pratik Vikram Jakhelia	Non-executive & Independent Director
5.	Mr. Manish Bhagwandas Ved	Non-executive & Independent Director
6.	Mr. Ashvin Jamnadas Ganatra	Non-executive & Independent Director



B. RETIREMENT BY ROTATION

In accordance with the provisions of Section 152(6) and other applicable provisions of the Act, Mrs. Jagruti Atul Vasani (DIN: 02107094) will retire by rotation at the ensuing Annual General Meeting of the Company and being eligible, offers herself for re-appointment and will continue as Whole-Time Director of the Company. The Board recommends her re-appointment.

17. KEY MANAGERIAL PERSONNEL

Pursuant to Section 2(51) of the Companies Act, 2013, read with the Rules framed there under, the following persons have been designated as Key Managerial Personnel of the Company;

1. Mr. Hemanth Damodar Pathak - Chief Executive Officer
2. Mr. Ratnesh Raghunath Singh - Chief Financial Officer
3. Ms. Vishwa Bipinbhai Mekhia - Company Secretary and Compliance Officer

18. INDEPENDENT DIRECTORS DECLARATION

The Independent Directors were appointed at the Board meeting and hold office for a fixed term not exceeding five years and are not liable to retire by rotation. In accordance with Section 149(7) of the Companies Act 2013, All Independent Directors of the Company have submitted the requisite declarations confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Act read with Regulation 16 and 25(8) of SEBI Listing Regulations. The Independent Directors have also confirmed that they have complied with Schedule IV of the Act and the Company's Code of Conduct.

19. FAMILIARIZATION PROGRAMME

The Familiarization Programme for Independent Directors aims to provide them an opportunity to familiarize with the Company, its Management and its operations so as to gain a clear understanding of their roles, rights and responsibilities and contribute significantly towards the growth of the Company. They have full opportunity to interact with Senior Management Personnel and are provided all the documents required and sought by them for enabling them to have a good understanding of the Company, its business model and various operations and the industry of which it is a part. The policy undertaken by the Company in this respect has been disclosed on the website of the Company at <https://www.vaishalipharma.com/investors/company-policy>.

20. VIGIL MECHANISM

Pursuant to the provisions of Section 177 (9) & (10) of the Act read with Rule 7 of the Companies (Meeting of Board and its Powers) Rules, 2014, Vigil Mechanism for Directors and employees to report genuine concern and grievances has been established. The said mechanism is governed by the Audit Committee. The details of the policy is available on the website of the company at <https://www.vaishalipharma.com/investors/company-policy>.

21. BOARD AND DIRECTOR'S EVALUATION

The Board of Directors has carried out an annual evaluation of its own performance, Board, Committees and Individual Directors pursuant to the provisions of the Act and the Corporate Governance requirements as prescribed by Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("SEBI Listing Regulations").

The performance of the Board was evaluated by the Board Members after seeking inputs from all the Directors on the basis of the criteria such as the Board composition and structure, effectiveness of Board processes, information and functioning, etc.

The performance of the Committees was evaluated by the Board after seeking inputs from the Committee Members on the basis of the criteria such as the composition of Committees, effectiveness of Committee Meetings, etc.

The Board and the Nomination and Remuneration Committee reviewed the performance of the Individual Directors on the basis of the criteria such as the contribution of the Individual Director to the Board and Committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc.

In a separate meeting of Independent Directors, performance of Non-Independent Directors, performance of the Board as a whole and performance of the Chairman was evaluated, taking into account the views of Executive Directors and Non-Executive Directors. The same was discussed at the Board Meeting that followed the meeting of the Independent Directors, at which the performance of the Board, its Committees and Individual Directors was also discussed. Performance evaluation of Independent Directors was done by the entire Board, excluding the Independent Director being evaluated.

22. REMUNERATION POLICY

The Board has adopted a policy for selection and appointment of Directors, Senior Management and their remuneration in order to comply with the requirement under the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. The brief information about Remuneration Policy is provided in the Corporate Governance Report which is annexed to this report.

The policy of the Company on director's appointment and remuneration is uploaded on to the Company's website and available at <https://www.vaishalipharma.com/investors/company-policy/>.

23. MEETINGS OF THE BOARD:

Total Eight (8) Board Meetings were held during the financial year 2022 - 2023. For details of the meeting of the Board please refer to the Corporate Governance Report which is a part of this report.

24. CONSTITUTION OF COMMITTEES

In compliance of SEBI Listing Regulations and provisions of Companies Act, 2013, the Board of Directors constituted three Committees to comply with the requirements of listing, the Company has constituted the following Committees

1. Audit Committee
2. Nomination and Remuneration Committee
3. Stakeholder Relationship Committee

25. AUDIT COMMITTEE

Total Eight (8) Audit Committee Meetings were and held during the financial year 2022 - 2023. For details of the meeting and the composition of the Committee, kindly refer the Corporate Governance Report, which is a part of this report.

26. NOMINATION AND REMUNERATION COMMITTEE

Total Four (4) Nomination and Remuneration Committee Meetings were and held during the financial year 2022 - 2023. For details of the meeting and the composition of the Committee, kindly refer the Corporate Governance Report, which is a part of this report.

In accordance with the provisions of the Section 178 of the Companies Act, 2013 read along with the applicable Rules, the Company has formulated "Nomination and Remuneration Policy" containing criteria for determining qualifications, positive attributes, independence of a director and other matters provided under section 178 of Companies Act, 2013 for selection of any Director, Key Managerial Personnel and Senior Management Employees.



The said policy is available on the Company's website and the web link thereto is <https://www.vaishalipharma.com/investors/company-policy>.

27. STAKEHOLDER RELATIONSHIP COMMITTEE

Total Four (4) Stakeholder Relationship Committee Meetings were and held during the financial year 2022 - 2023. For details of the meeting and the composition of the Committee kindly refer the Corporate Governance Report, which is a part of this report.

28. AUDITORS

a. STATUTORY AUDITORS

In accordance with the provisions of Section 139 of the Companies Act, 2013 and Companies (Audit and Auditors) Rules, 2014, M/s Raman S. Shah & Associates, Chartered Accountants, having Firm Registration No. : 119891W has been appointed as Statutory Auditors of the Company by the members at their 15th Annual General Meeting held on September 30, 2022 to hold office for second term of five consecutive years i.e. till the conclusion of Annual General Meeting for the financial year 2026-2027.

There being no qualification or adverse remark in the Auditor's Report and hence, the report is self-explanatory.

b. INTERNAL AUDITOR

M/s. R. U. Kamath & Co., Chartered Accountants has been re-appointed as internal Auditor for the Financial Year 2023-2024.

The Internal Auditors reports to the Audit Committee of the Board, which helps to maintain its objectivity and Independence. The scope and authority of the Internal Audit function is defined by Audit Committee.

c. SECRETARIAL AUDITOR

In compliance with the provisions of Section 204 of the Companies Act, 2013, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and SEBI Listing Regulation, as amended, the Board of Directors has, on the recommendation of Audit Committee considered re-appointment of M/s. Disha & Associates, Practicing Company Secretaries, as Secretarial Auditors of the Company for conducting Secretarial Audit for financial year 2023 - 2024.

The Secretarial Auditor's Report for Financial Year 2022-23 is annexed herewith as **ANNEXURE – B**.

29. MAINTENANCE OF COST RECORDS

The maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of the Section 148 of the Act in respect of the activities carried on by the Company.

30. SECRETARIAL STANDARDS

The Directors declared that applicable Secretarial Standards relating to 'Meetings of the Board of Directors' and 'General Meetings' respectively, has been duly followed.

31. CORPORATE GOVERNANCE

Your Company is committed to maintain the highest standards of corporate governance. We believe in adherence to good corporate practices, implement policies and guidelines and develop a culture of the best management practices and compliance with the law coupled with the highest standards of integrity, transparency, accountability and ethics in all business matters to enhance and retain investor trust, long-term shareholder value and respect minority rights in all our business decisions.

The Corporate Governance Report of the Company confirming compliance with the conditions of corporate governance as stipulated under SEBI Listing Regulations forms part of the Annual Report.

The Certificate on Corporate Governance Compliance issued by Secretarial Auditor is enclosed in **ANNEXURE – C**.

32. CORPORATE SOCIAL RESPONSIBILITY

As the provisions of section 135 of Companies Act, 2013 dealing with Corporate Social Responsibility are applicable to the Company during the financial year, the Corporate Social Responsibility Policy of the Company is available on the website of the Company at <https://www.vaishalipharma.com/investors/company-policy/>

Further, the Corporate Social Report activities carried out for FY21-22 forms part of the Annual Report, enclosed at **ANNEXURE -D**.

33. PARTICULARS OF EMPLOYEES

No employee was employed by the Company receiving remuneration prescribed under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (Rules) and the rules framed thereunder.

Disclosures with respect to the remuneration of Directors and employees as required under Section 197 of the Act and Rule 5 (1) of the Rules have been appended as **ANNEXURE - E** to this report.

34. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management Discussion and Analysis Report for the financial year 2022 - 2023, as stipulated under Regulation 34(2)(e) of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "the SEBI LODR"), is presented in a separate section forming part of the Annual Report as **ANNEXURE - F**.

35. DEMATERIALISATION OF EQUITY SHARES AND SHARE WARRANTS

Equity Shares and Share warrants of the Company are in dematerialized form with Depositories viz. NSDL and CDSL.

The Equity ISIN No. allotted is **INE972X01014**.

The Share Warrant ISIN No. allotted is **INE972X13019**.

36. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company is committed and dedicated in providing a healthy and harassment free work environment to every individual of the Company, a work environment that does not tolerate sexual harassment. We highly respect dignity of everyone involved at our work place, whether they are employees, suppliers or our customers. We require all employees to strictly maintain mutual respect and positive attitude towards each other.



The Company has adopted a policy for prevention of Sexual Harassment of Women at Workplace. No complaints or grievances were noticed under the aforesaid policy during the period under review.

The Company has complied with the provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

As on the date of this report, the constitution of the Internal Complaints Committee is as under:

Sr. No.	Name of the Member	Post of the Committee members	Designation
1	Presiding Officer	Mrs. Jagruti Vasani	Whole – Time Director
2	Member	Mr. Atul Vasani	Chairman & Managing Director
3	Member	Ms. Priyanka Vasani	Chief Operating Officer
4	Member	Mrs. Medha Desai	Management representative

37. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

a) CONSERVATION OF ENERGY & TECHNOLOGY ABSORPTION

Considering the nature of activities undertaken by the company, above clauses of Section 134 of the Companies Act, 2013 pertaining to the Conservation of Energy, Technology absorption are not applicable to the Company.

b) FOREIGN EXCHANGE EARNINGS AND OUTGO

During the year there were foreign exchange inflow of Rs. 1755.31 Lakhs (P.Y. - Rs. 1384.44 Lakhs) on account of export of goods on FOB basis and foreign outflow as follows:-

(₹ in Lakhs)

Expenditure in Foreign Currency	Current Year (₹ in Lakhs)	Previous Year (₹ in Lakhs)
Import of Goods (on CIF basis)	541.93	393.44
Foreign Travelling	6.77	5.96
Registration Charges	1.39	7.05
Inspection Charges	0	0.19
Gross Total	550.10	406.65

38. INSURANCE & RISK MANAGEMENT

Business risks exist for any enterprise having national and international exposure. Your Company also faces some such risks, the key ones being - a longer than anticipated delay in economic revival, unfavorable exchange rate fluctuations, emergence of inflationary conditions, rise in counterfeits and look-alikes and any unexpected changes in regulatory framework.

The Company is well aware of these risks and challenges and has put in place mechanisms to ensure that they are managed and mitigated with adequate timely actions.

39. ACKNOWLEDGEMENTS

The Directors thank the Company's employees, investors and academic partners for their continuous support.

The Directors also thank the Government of India, Governments of various states in India, Governments of various countries and concerned Government departments and agencies for their co-operation.

Your Directors are thankful to the Vendors, Customers, Bankers, and Government together with their departments and the local authorities, Employees, Stakeholders for their valuable support and co-operation.

Date: September 05, 2023

Place: Mumbai

For and on behalf of the Board of Directors

Vaishali Pharma Limited

Sd/-

Atul Vasani

Chairman & Managing Director

DIN:- 02107085

Registered Office:-706 to 709, 7th Floor, Aravali

Busines Center, R. C. Patel Road,

Off Sodawala Lane, Borivali-

West, Mumbai - 400092



ANNEXURE - A

FORM NO. AOC -2
(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and
Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

Particulars	Details
Name (s) of the related party & nature of relationship	NIL
Nature of contracts/arrangements/transaction	
Duration of the contracts/arrangements/transaction	
Salient terms of the contracts or arrangements or transaction including the value, if any	
Justification for entering into such contracts or arrangements or transactions'	
Date of approval by the Board	
Amount paid as advances, if any	
Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of material contracts or arrangements or transactions at Arm's length basis.

Particulars	Details
Name (s) of the related party & nature of relationship	NIL
Nature of contracts/arrangements/transaction	
Duration of the contracts/arrangements/transaction	
Salient terms of the contracts or arrangements or transaction including the value, if any	
Date of approval by the Board	
Amount paid as advances, if any	

Date: September 05, 2023

Place: Mumbai

For Vaishali Pharma Limited

Sd/-
Atul Vasani
Chairman &
Managing Director
DIN:- 02107085

Sd/-
Jagruti Vasani
Whole Time
Director
DIN:-02107094

ANNEXURE - B

Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED MARCH 31, 2023
[Pursuant to section 204(1) of the Companies Act, 2013 and rule no. 9 of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To the Members
Vaishali Pharma Limited
CIN: L52310MH2008PLC181632

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Vaishali Pharma Limited (hereinafter called 'the Company'). Secretarial Audit was conducted in a manner that provided a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit of the Company, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on March 31, 2023 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2023 according to the provisions of:

- i. The Companies Act, 2013 (the Act) and the rules made thereunder;
- ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- iii. The Depositories Act, 1996 and the Regulations and Byelaws framed thereunder;
- iv. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; *Not applicable to the Company during the Audit Period.*
- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 - d. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; *Not applicable to the Company during the Audit Period*
 - e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; *Not applicable to the Company during the Audit Period*
 - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;



- g. The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ;
 - h. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; *Not applicable to the Company during the Audit Period.*
 - i. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; *Not applicable to the Company during the Audit Period.*
 - j. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- vi. Other laws applicable specifically to the Company namely:

I further report that, based on the Compliance Report of various Laws submitted by the Company, the Company has proper system to comply with the applicable laws. I have in-principally verified existing systems and mechanism which is followed by the Company to ensure compliance of other applicable laws and have relied on the representation made by the Company and its Officers in respect of aforesaid systems and mechanism for compliances of other applicable acts, laws and regulations and found the satisfactory operation of the same.

I have also examined compliance with the applicable clauses of Secretarial Standards with regards to Meeting of Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India and I am of opinion that the Company has prima facie complied with the applicable provisions.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following disclaimer/observations:

It is informed that the Company had not submitted the voting results in the XBRL form and the format as per the Reg. 44(3) of Securities and Exchange Board OF India (listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 for the Extra-ordinary General Meeting on January 04, 2023. In this connection, the National Stock Exchange of India Limited had imposed a fine of Rs.10,000/- on the Company for violation of Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in the month of January 2023. The same has been paid by the Company on February 16, 2023.

I further report that the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. As, informed, there was no change in the composition of the Board of Directors of the Company during the financial year under review.

Adequate notice is given to all the Directors to schedule the Board Meetings, except for a meeting which was convened at a shorter notice to transact urgent business, which were compliant with the provisions of the Act as prescribed. Agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All the decisions of the Board are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors.

I, further, report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines subject to observations and qualifications, if any, made by Statutory Auditors in their report.

I, further, report that I have not examined books of accounts and I rely on statutory auditor's reports in relation to Financial Statement and accuracy of financial figures for Sales Tax, Value Added tax, Goods and Service Tax Act, Tax Deducted at Source, Provident fund, Professional Tax, Related Party Transactions, etc. as disclosed under

financial statements and Accounting Standards during my audit period and I have not verified the correctness and appropriateness of the books of accounts of the Company.

I, further, report that the management is responsible for compliances of all business laws along with maintenance of statutory registers / records required by the concerned authorities and internal control of the concerned department.

I, further, report that during the year under review, the Company issued 25,00,000 (Twenty-Five Lakhs) convertible Share Warrants, on a preferential basis, at an issue price of Rs. 121.82/- (Rupees One Hundred Twenty One Rupees and Eighty Two Paise Only) per warrant. For the same, the Company received "In-Principle approval" of the National Stock Exchange of India Limited (vide its letter reference no. NSE/LIST /33669) dated January 24, 2023. Furthermore, the Board allotted 25,00,000 (Twenty-Five Lakhs) convertible Share Warrants on 7th February 2023 to the allottees.

Apart from this, there were no major activities during the period under review.

I, further, report that:

- i. Maintenance of Secretarial record is the responsibility of the Management of the Company. My responsibility is to express an opinion on these Secretarial Records based on my audit.
- ii. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in the Secretarial records. I believe that the processes and practices, I followed provide a reasonable basis for my opinion.
- iii. Wherever required, I have obtained the Management representation about the compliance of Laws, Rules and Regulations and happening of events etc.
- iv. The compliance of the provisions of Corporate and other applicable Laws, Rules, Regulations, Standards is the responsibility of the Management. My examination was limited to the verification of procedures on test basis.
- v. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

For **M/s. Disha & Associates,**

Sd/-

Disha Shah

Practicing Company Secretary

Proprietor

Membership No: A34831/ COP No: 22710

UDIN: A034831E000946940

Peer Review Certificate No.: 1968/2022

Date: September 05, 2023

Place: Mumbai



ANNEXURE – C

REPORT ON CORPORATE GOVERNANCE

In compliance with Regulation 34(3) and Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), a Report on Corporate Governance for the Financial Year 2022 - 2023 is presented below:

I. COMPANY’S PHILOSOPHY ON CORPORATE GOVERNANCE

Effective corporate governance practices constitute the strong foundation on which successful commercial enterprises are built to last. The Company’s philosophy on corporate governance oversees business strategies and ensures fiscal accountability, ethical corporate behavior and fairness to all stakeholders comprising regulators, employees, customers, vendors, investors and the society at large.

The Company has a strong legacy of fair, transparent and ethical governance practices.

The Company believes that sound corporate governance is critical to enhance and retain investor trust. Hence our business policies are based on ethical conduct, health, safety and a commitment to building long term sustainable relationships with relevant stakeholders. The Company continues to strengthen its governance principles to generate long term value for all its stakeholders on a sustainable basis thus ensuring ethical and responsible leadership both at the Board and at the Management levels.

The Company is in compliance with the requirements stipulated under Regulation 17 to 27 read with Schedule V and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as applicable, with regard to corporate governance.

A report on compliance with corporate governance principles as prescribed under Regulation 17 to 27 read with Schedule V of SEBI Listing Regulations, as applicable, is given below.

II. BOARD OF DIRECTORS

1. COMPOSITION AND CATEGORY OF DIRECTORS

The Company’s Board has an optimum combination of Executive including a Woman Director and Non-Executive Directors. The Board of Directors as at the end of March 31, 2023, comprised of Six (6) Directors, out of which Three (3) Directors are Executive Directors, and Three (3) Non-Executive & Independent Directors.

The Company’s day-to-day affairs are subject to supervision and control of the Board of Directors. The Directors bring to the Board multifacet of experience, diversity and skills required for its successful business operations/ performance.

The names and categories of the Directors on the Board, the number of Directorships and Committee Chairmanships / Memberships held by them in other public limited companies as on March 31, 2023 are given herein below. Other directorships do not include directorships of private limited companies, foreign companies and companies registered under Section 8 of the Act. Further, none of them is a member of more than ten committees or chairman of more than five committees across all the public companies in which he / she is a Director. For the purpose of determination of limit of the Board Committees, chairpersonship and membership of the Audit Committee and Stakeholders’ Relationship Committee has been considered as per Regulation 26(1) (b) of SEBI Listing Regulations.

The composition of the Board and Other Directorship / Committee Position, etc. as of March 31, 2023, is given below

Name of Director	Category and Designation	Number of Directorships in other Public Companies		Number of Committee positions held in other Public Companies		Directorship in other listed entity (Category of Directorship)	No. of Equity Shares Held	No. of Share Warrant Held (Convertible)
		Chairman	Member	Chairman	Member			
Mr. Atul Vasani (DIN:- 02107085)	Chairman & Managing Director	-	-	-	-	-	22,62,023	8,52,000
Mrs. Jagruti Vasani (DIN:- 02107094)	Whole-Time Director	-	-	-	-	-	4,79,992	2,00,000
Mr. Dewansh Vasani (DIN:- 08111804)	Executive Director	-	-	-	-	-	1	1,00,000
Mr. Ashvin Ganatra (DIN:- 08653815)	Non-Executive Director & Independent Director	-	-	-	-	-	NIL	NIL
Mr. Manish Ved (DIN:- 08654674)	Non-Executive Director & Independent Director	-	-	-	-	-	NIL	NIL
Mr. Patik Jakhelia (DIN:- 07726752)	Non-Executive Director & Independent Director	-	-	-	-	-	NIL	NIL

Notes:

- None of the Directors serve as a Director in more than seven listed companies. Further, none of the Directors serves as an ID in more than seven listed companies or three listed companies in case he/she serves as an ED in any listed company. None of the Directors on the Board are a member of more than 10 committees and a chairperson of more than 5 committees, across all public limited companies in which he/she is a Director. Further, none of our IDs serve as Non-Independent Director of any company on the board of which any of our Non-Independent Director is an ID.
- Does not include Directorship in Foreign Companies

2. BOARD MEETINGS

The Board conducts regular scheduled meetings on a quarterly basis. The Company in consultation with the Directors prepares the Annual calendar of meetings and circulates a tentative Schedule for the meeting of the Board and Committee in order to facilitate the Directors to plan their schedules. During the year under review the Board met on 8 occasion's i.e.

April 01, 2022	May 30, 2022	July 25, 2022
September 01, 2022	November 03, 2022	December 05, 2022
February 06, 2023	February 07, 2023	



3. ATTENDANCE RECORD OF BOARD MEMBERS

The attendance record of all the Directors at the Board Meetings and the last Annual General Meeting between April 01, 2022 to March 31, 2023 is as under: -

Sr. No.	Name of Director	Category of Directorship	No. of Board Meetings held	No. of Board Meetings Attended	Last AGM Attended
1	Mr. Atul Vasani	Chairman & Managing Director	8	8	Yes
2	Mrs. Jagruti Vasani	Whole-Time Director	8	8	Yes
3	Mr. Dewansh Vasani	Executive Director	8	8	Yes
4	Mr. Ashvin Ganatra	Independent Director	8	8	Yes
5	Mr. Manish Ved	Independent Director	8	8	Yes
6	Mr. Patik Jakhelia	Independent Director	8	8	Yes

The maximum gap between two Board Meetings was less than 120 days. The minutes of the meetings of all the Board and Committees are circulated to all the Directors after incorporating the comments of the Directors.

4. DISCLOSURE OF RELATIONSHIPS BETWEEN DIRECTORS

Sr. No.	Name of Directors	Designation	Relationship
1	Mr. Atul Arvind Vasani	Managing Director	Husband of Mrs. Jagruti Atul Vasani
2	Mrs. Jagruti Atul Vasani	Whole-Time Director	Wife of Mr. Atul Arvind Vasani
3	Mr. Dewansh Ajay Vasani	Executive Director	Brother's Son of Mr. Atul Arvind Vasani
4	Mr. Ashvin Ganatra	Independent Director	-
5	Mr. Manish Ved	Independent Director	-
6	Mr. Patik Jakhelia	Independent Director	-

5. INDEPENDENT DIRECTORS

The Company has received a declaration from the Independent Directors confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Act read with Regulation 16(1)(b) of the SEBI Listing Regulations.

In the opinion of the Board, the Independent Directors fulfil the conditions of independence specified in the Act and the SEBI Listing Regulations and are independent of the Management. Further, the Independent Directors have in terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment & Qualification of Directors) Rules, 2014, as amended, confirmed that they have enrolled themselves in the Independent Directors' Databank maintained with the Indian Institute of Corporate Affairs ('IICA').

• MEETING OF INDEPENDENT DIRECTOR

During the year under review, one (1) Meeting of the Independent Directors of the Company was held on April 01, 2022 which was attended by all IDs., Mr. Pratik Vikram Jakhelia Independent Director chaired the meeting.

• TERMS AND CONDITIONS OF APPOINTMENT OF INDEPENDENT DIRECTORS

All the Independent Directors of the Company have been appointed as per the provisions of the Act and the SEBI Listing Regulations. Formal letters of appointment are issued to the Independent Directors after their appointment by the Members. As required by Regulation 46 of the SEBI Listing Regulations, the terms and conditions of their appointment have been disclosed on the website of the Company at <https://www.vaishalipharma.com/investors/company-policy/documents/Terms-and-Conditions-of-ID.pdf>

• FAMILIARISATION PROGRAMME TO INDEPENDENT DIRECTORS

As per SEBI Listing Regulation, the Board has appointed three Independent Directors. Pursuant to Regulation 25(7) of the SEBI Listing Regulations, the Company imparted familiarization program for the Independent Directors with respect to their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, the business model of the Company etc.

The familiarisation programme along with details of the same imparted to the Independent Non-Executive Directors during the year are available on the website of the Company at <https://www.vaishalipharma.com/>

The Company would also encourage existing directors to attend seminars and trainings to enable them to keep pace with changes of regulatory and financial reporting standards that have a material bearing on the Company and its industry. The policy on familiarization program for Independent Directors are available on the Company's website at <https://www.vaishalipharma.com/investors/company-policy>.

6. SKILLS / EXPERTISE / COMPETENCIES OF BOARD OF DIRECTORS:

The Core skills / expertise / competencies as identified by the Board of Directors, with a view to ensure effective functioning of the Company and as possessed by its directors with respect to the Company's operational affairs, are stated as hereunder:

Skills / expertise / competencies identified by the Board of Directors as required in the context of its business and sectors	Names of the Directors who have such skills / expertise / competencies
Leadership and Media Sector	Mr. Atul Vasani
Retail Marketing	Mr. Dewansh Vasani, Mr. Ashvin Ganatra
Accounts and Finance, Financial Management, Taxation	Mr. Atul Vasani, Mr. Dewansh Vasani Mr. Pratik Jakhelia
Corporate Governance, Administration	Mrs. Jagruti Vasani
Legal and Compliance	Mr. Atul Arvin Vasani
Business Strategy and Management	Mr. Atul Vasani Mr. Manish Ved, Mr. Ashvin Ganatra

7. CODE OF CONDUCT

The Company has adopted the Code of Conduct for its Whole-time Directors, Senior Management and other Executives which is available on the website of the Company at <https://www.vaishalipharma.com/investors/company-policy/documents/Code%20of%20Conduct%20for%20Directors%20and%20Senior%20Management.pdf>



All the members of the Board, the executive officers and senior officers have affirmed compliance to the Code as on March 31, 2023. A declaration to this effect, signed by the CEO, forms part of the CEO certification.

Declaration regarding compliance by board members and senior management personnel with the company's code of conduct is annexed herewith as **ANNEXURE – 1**

III. COMMITTEES OF THE BOARD

In compliance of SEBI Listing Regulation and provisions of Companies Act, 2013, the Board of Directors constituted three Committees the following Committees;

1. Audit Committee
2. Nomination and Remuneration Committee
3. Stakeholder Relationship committee

The terms of reference of the Committees are determined by the Board from time to time. The respective Chairman of the Committees also informs the Board about the summary of discussions held in the Committee Meetings. The Minutes of the Committee Meetings are tabled at the respective Committee Meetings.

1. AUDIT COMMITTEE

The Audit Committee acts as a link between the Statutory Auditors, Internal Auditors and the Board. The Committee is governed by regulatory requirements mandated by Section 177 of the Companies Act, 2013 and Regulation 18 of SEBI (LODR) 2015. The Committee has full access to financial information.

• TERMS OF REFERENCE

Committee is constituted in line with the provisions of Regulation 18 of SEBI Listing Regulations and Section 177 of the Companies Act, 2013.

- a) Oversight of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statements are materially correct, sufficient and credible;
- b) Evaluate auditors' performance, qualification, independence and effectiveness of audit process;
- c) Discuss and review with the Management and auditors, the annual/half-yearly/quarterly financial statements before submission to the Board for approval;
- d) Internal audit reports relating to internal control weaknesses; and
- e) Review the statement of related party transactions submitted by the Management;

• MEETINGS HELD

During Financial Year 2022-23, Eight (8) Meetings of the Audit Committee were held on the following dates:

April 01, 2022	May 30, 2022	July 25, 2022
September 01, 2022	November 03, 2022	December 05, 2022
February 06, 2023	February 07, 2023	

The gap between two Meetings did not exceed 120 days. Necessary quorum was present for all the Meetings of the Committee.

• ATTENDANCE

The attendance record of all the Directors (Members) at the Audit Committee Meeting between April 01, 2022 to March 31, 2023 are as under: -

Sr. No	Name	Category	Position	Attendance	
				Entitled	Attended
1	Mr. Manish Bhagwandas Ved	Independent Director	Chairman	8	8
2	Mr. Ashvin Jamnadas Ganatra	Independent Director	Member	8	8
3	Mr. Pratik Vikram Jakhelia	Independent Director	Member	8	8
4	Mr. Atul Arvind Vasani	Managing Director	Member	8	8

The Statutory Auditors, Internal Auditors, Cost Auditors and other relevant Senior Management Persons were invited to attend the meetings of the Audit Committee. The Company Secretary of the Company acts as Secretary to the Committee. Mr. Manish Bhagwandas Ved, Chairman of Audit Committee was present at the last Annual General Meeting held on September 30, 2022.

2. NOMINATION AND REMUNERATION COMMITTEE

The Nomination and Remuneration Committee ('NRC') is constituted and functions in accordance with Section 178 of the Act, Regulation 19 of the SEBI Listing Regulations and its Charter as approved by the Board.

• TERMS OF REFERENCE

The Board has adopted a charter of the Nomination and Remuneration Committee for its smooth functioning covering aspects relating to composition, responsibilities, evaluation process, remuneration, Board development and reviewing HR strategy. The key terms of reference of the NRC, inter alia, are:

- Recommend to the Board the setup and composition of the Board and its committees.
- Support the Board and Independent Directors, as may be required, in evaluation of the performance of the Board, its Committees and Individual Directors;
- Recommend to the Board the appointment / re-appointment of Directors and Key Managerial Personnel.
- Recommend the Board the remuneration Policy for Directors, executive team or Key Managerial Personnel as well as the rest of employees.
- Oversee the Familiarization programs for the Directors.

• MEETINGS HELD

During Financial Year 2022-23, Four (4) Meetings of the Nomination and Remuneration (NRC) Committee were held on the following dates:

May 30, 2022	September 01, 2022	November 03, 2022	February 06, 2023
--------------	--------------------	-------------------	-------------------

• ATTENDANCE

The attendance record of all the Directors (Members) at the Nomination & Remuneration Committee Meeting between April 01, 2022 to March 31, 2023 are as under: -



Sr. No	Name	Category	Position	Attendance	
				Entitled	Attended
1	Mr. Manish Bhagwandas Ved	Independent Director	Chairman	4	4
2	Mr. Ashvin Jamnadas Ganatra	Independent Director	Member	4	4
3	Mr. Pratik Vikram Jakhelia	Independent Director	Member	4	4

The Company Secretary of the Company acts as Secretary to the Committee. Mr. Manish Bhagwandas Ved, Chairman of Nomination and Remuneration Committee was present at the last Annual General Meeting held on September 30, 2022.

• PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS

The performance evaluation criteria for Independent Directors is determined by the Nomination and Remuneration Committee. An indicative list of factors on which evaluation was carried out includes participation and contribution by a director, commitment, effective deployment of knowledge and expertise, integrity and maintenance of confidentiality and independence of behavior and judgment.

• REMUNERATION OF DIRECTORS

- Based on the recommendations of the Nomination and Remuneration Committee, the Board has formulated Policy for Remuneration of Directors and Employees. The policy can be accessed on the following link <https://vaishalipharma.com/investors/company-policy/>.
- There were no pecuniary relationships or transactions between the Non-Executive Directors and the Company during the Financial Year 2023, save and except remuneration drawn as mentioned below.
- Executive Directors are paid remuneration in the form of salary, perquisites and commission in accordance with the Remuneration Policy and limits prescribed under the Act. No royalty has been paid to the Promoter or Promoter Group during the year.
- The Company pays sitting fees of Rs. 1,100/- (One Thousand and One Hundred) per meeting to its Independent Directors for attending meetings of the Board and meetings of committees of the Board.
- The Company does not pays any commission to the Non-Executive Directors. The Company also reimburses the out-of-pocket expenses, if any incurred by the Directors for attending the meetings.
- No stock options were issued to any Directors during the year.
- Remuneration paid to Executive and Non-Executive Directors during the year ended March 31, 2023:

Name of Directors	Remuneration	Sitting Fees	Commission	Total Amount (Rs.)
Mr. Atul Arvind Vasani (MD)	54,00,000	-	-	54,00,000
Mrs. Jagruti Atul Vasani (WTD)	12,00,000	-	-	12,00,000
Mr. Dewansh Ajay Vasani (ED)	12,00,000	-	-	12,00,000
Mr. Pratik Vikram Jakhelia (ID)	-	8,800	-	8,800
Mr. Manish Bhagwandas Ved (ID)	-	8,800	-	8,800
Mr. Ashvin Jamnadas Ganatra (ID)	-	8,800	-	8,800

The Company Secretary of the Company acts as Secretary to the Committee. Mr. Manish Bhagwandas Ved, Chairman of Nomination and Remuneration Committee was present at the last Annual General Meeting held on September 30, 2022.

3. STAKEHOLDER RELATIONSHIP COMMITTEE

The Stakeholders Relationship Committee has been constituted as per the requirement of 178 of the Companies Act, 2013 and Regulation 20 of SEBI Listing Regulations.

• TERMS OF REFERENCE

The terms of reference of the Shareholder's/ Investors Relationship Committee include the following:

The terms of reference of the Stakeholders Relationship Committee (SRC) covers the areas mentioned in Section 178 (5) of the Act and Regulation 20 read with Part D (B) of Schedule II to the Listing Regulations. The terms of reference of the SRC, inter-alia are as follows:

- To allot equity shares and other securities of the Company
- Allotment and listing of shares
- Consider and resolve the grievances of the Security holders.
- Consider and approve Issue of share certificates, transfer and transmission of securities, etc.
- And to otherwise ensure proper and timely attendance and redressal of investor queries and grievances.
- Review activities with regard to the Health Safety and Sustainability Initiatives of the Company.

• MEETINGS HELD

During Financial Year 2022-23, Four (4) Meetings of the Stakeholders Relationship Committee were held on the following dates:

May 30, 2022	September 01, 2022	November 03, 2022	February 06, 2023
--------------	--------------------	-------------------	-------------------

• ATTENDANCE

The attendance record of all the Directors (Members) at the Stakeholders Relationship Committee Meeting between April 01, 2022 to March 31, 2023 are as under: -

Sr. No	Name	Category	Position	Attendance	
				Entitled	Attended
1	Mr. Manish Bhagwandas Ved	Independent Director	Chairman	4	4
2	Mr. Ashvin Jamnadas Ganatra	Independent Director	Member	4	4
3	Mr. Pratik Vikram Jakhelia	Independent Director	Member	4	4

The Company Secretary of the Company acts as Secretary to the Committee. Mr. Manish Bhagwandas Ved, Chairman of Stakeholders Relationship Committee was present at the last Annual General Meeting held on September 30, 2022.



• NAME, DESIGNATION AND CONTACT DETAILS OF COMPLIANCE OFFICER

Ms. Vishwa Bipinbhai Mekhia, Company Secretary (ICSI M. No: A62287) is the Compliance Officer for complying with the requirements of the Securities Laws, Listing Agreements with the Stock Exchanges and SEBI Listing Regulations, 2015. She acts as the Secretary to all the mandatory sub-committees of the Board.

• INVESTOR COMPLAINT DETAILS FOR THE FINANCIAL YEAR 2022-2023

Details of investor complaints received and redressed during F.Y. 2022 - 2023 are as follows:

Opening balance	Received during the year	Resolved during the year	Closing balance
0	1	1	0

• SENIOR MANAGEMENT

There were no changes in the senior management since the close of the previous financial year.

4. GENERAL BODY MEETINGS

- a. Annual General Meetings are generally held within 6 (Six) months from the end of financial year. AGMs during last 3 years were held on:

AGM	Date	Time	Venue	Details of Special Resolution passed
13 th	September 30, 2020	11:00 am	Meeting held through VC	1. Appointment of Mr. Ashvin Jamnadas Ganatra (DIN - 08653815) as an Independent Director of the Company 2. Appointment of Mr. Manish Bhagwandadas Ved (DIN - 08654674) as an Independent Director of the Company
14 th	September 30, 2021	11:00 am	Meeting held through VC	1. To appoint Mr. Pratik Vikram Jakhelia (DIN - 07726752) as an Independent Director of the Company 2. Annual Remuneration payable to the Promoter, Executive Director/ Member of the promoter Group exceeding 5% of the Net Profit of the Company as per Section 198 of the Companies Act, 2013.
15 th	September 30, 2022	11:00 am	Meeting held through VC	1. Re-appointment of Mr. Atul Vasani as Managing Director 2. Re-appointment of Mrs. Jagruti Vasani as Whole-Time Director

- b. Extraordinary General Meeting (EGM) of the members was held on January 04, 2023;

i. Issue of Securities on Preferential Basis

25,00,000 (Twenty five lakhs) warrants, each convertible into, or exchangeable for, 1 (one) fully paid-up equity share of the Company of face value of ₹ 10/- each ('Warrants'), which may be exercised in one or more tranches during the period commencing from the date of allotment of the Warrants until expiry of 18 (Eighteen) months, at a price of ₹ 121.82/-

ii. Voting Results - 42 Members were cast their votes with holding of 3007408 Equity Shares.

Category	Mode of Voting	No. of Shares held (1)	No. of Votes polled (2)	% of Votes polled on outstanding shares (3)=[(2)/(1)]* 100	No. of votes in favour (4)	No. of Votes against (5)	% of votes in favour on votes polled (6)=[(4)/(2)]*100
Promoter and Promoter Group	E-Voting	2820270	2820270	100	2820270	0	100
	Poll	0	0	0	0	0	0
	Postal Ballot	0	0	0	0	0	0
	Total	2820270	2820270	100	2820270	0	100
Public - Institution	E-Voting	0	0	0	0	0	0
	Poll	0	0	0	0	0	0
	Postal Ballot	0	0	0	0	0	0
	Total	0	0	0	0	0	0
Public – non Institution	E-Voting	187138	187138	100	187138	0	100
	Poll	0	0	0	0	0	0
	Postal Ballot	0	0	0	0	0	0
	Total	187138	187138	100	187138	0	100
Total		3007408	3007408	100	3007408	0	100

- Notice of AGM is sent to Shareholders at clear 21 days prior to the meeting date and the same is also made available on the Company and Stock Exchange(s) websites.
- E-voting facility is provided at general meetings to enable the Shareholders vote electronically. Proper instructions w.r.t. the e-voting are circulated to all the Shareholders and they are assisted to vote electronically in case of any difficulty.
- All the Board Members, Statutory Auditors, Secretarial Auditor attend the AGMs.
- Company had provided remote e-voting facility to enable all its members to cast their votes electronically before the General Meeting and throughout the meeting
- Result of e-voting are available on the Stock Exchange(s) & Company's website.

IV. MEANS OF COMMUNICATION

Company communicates with its stakeholders through multiple channels such as disclosures, press releases, analyst meetings, investor calls, as also through social media.

a) NEWSPAPERS

The Audited / Unaudited Quarterly / Half-yearly / yearly financial statements are announced within statutory timeline. The aforesaid financial statements reviewed by the Audit Committee are taken on record by the Board of Directors and are communicated to the Stock Exchange where the Company's securities are listed. Once the Stock Exchanges have been intimated, these results are given by way of a press release to news agency and published within 48 hours in two leading daily newspapers – one in English and one in Marathi.



b) WEBSITE

Company's website contains a dedicated section 'Investors' wherein information appropriate/useful for shareholders is available. Investor information on website is accessible, accurate and comprehensive. Contact of Investor Relation person is also placed on website.

c) ANNUAL REPORT

The Company has been sending Annual Report, Notices and other communications only via e-mail to those shareholders whose e-mail IDs are registered with the Depositories/Registrar & Share Transfer Agent ("RTA"). Notice and Annual Report are also available on the website of the Company and the National Stock Exchange of India Limited.

d) FILING WITH THE STOCK EXCHANGES

All periodical compliance filings like Shareholding Pattern, Corporate Governance Report, and Press Releases are electronically filed with The National Stock Exchange of India Limited (NSE) respectively, the Company also timely disseminates on the website of Stock Exchanges, all price sensitive matters or such other matters which in its opinion are material and have relevance to the shareholders, they are also available on website.

V. GENERAL SHAREHOLDERS INFORMATION


1. Annual General Meeting Details:
16th AGM to be held on September 29, 2023 at 12:00 noon through video-conferencing or other Audio- Visual Means
2. Record Date : September 23, 2023
3. Dividend Payment : No Dividend is declared for the F.Y. 2022 – 2023
4. Listing on Stock Exchanges : National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra - Kurla Complex,
Bandra (East), Mumbai 400 051.
5. Symbol : VAISHALI
6. Corporate Identity Number (CIN) : L52310MH2008PLC181632
7. Stock Market Price Data:

During the period under review, the Market price Data from April 01, 2022 is available on NSE and placed as under:-

High, Low (based on daily closing prices) and number of equity shares traded during each month in the Financial Year 2022 – 2023 is as follows:-

Month	NSE		Total number of Equity Shares Traded
	High (Rupees)	Low (Rupees)	
APR – 2022	119.30	64.35	14,448,357
MAY – 2022	93.00	68.35	955,539
JUN – 2022	87.40	72.50	1,354,541
JUL – 2022	92.75	79.95	1,342,012
AUG – 2022	104.00	85.00	2,943,237
SEP – 2022	108.85	91.05	2,627,750
OCT – 2022	107.00	95.05	1,730,000
NOV – 2022	127.85	95.05	5,219,586
DEC – 2022	162.00	121.20	8,766,443

JAN – 2023	166.55	136.05	6,177,797
FEB – 2023	193.75	122.10	7,356,903
MAR – 2023	186.30	143.45	3,092,076



The Equity Shares of the Company were not suspended from trading.

8. SHARE TRANSFER SYSTEM

In terms of Regulation 40(1) of SEBI Listing Regulations, as amended, securities can be transferred only in dematerialized form w.e.f. April 1, 2019, except in case of request received for transmission or transposition of securities. Transfers of equity shares in electronic form are effected through the depositories with no involvement of the Company. The Directors and certain Company officials (including Chief Financial Officer and Company Secretary) are authorized by the Board severally to approve transfers, which are noted at subsequent Board Meetings.

9. SHAREHOLDING AS ON MARCH 31, 2023

A. DISTRIBUTION OF EQUITY SHAREHOLDING AS ON MARCH 31, 2023

Sr. No	Shareholding of Nominal		Number of Shareholders	% to Total	Shares	% to Total
1	1	500	8289	87.18	652207	6.18
2	501	1000	474	4.99	381401	3.62
3	1001	2000	273	2.87	414433	3.93
4	2001	3000	147	1.55	372918	3.54
5	3001	4000	68	0.72	241635	2.29
6	4001	5000	47	0.49	219199	2.08
7	5001	10000	110	1.16	793199	7.52
8	10001	99999999	100	1.05	7471221	70.84
TOTAL			9508	100	10546213	100

B. CATEGORIES OF EQUITY SHAREHOLDING AS ON MARCH 31, 2023

Category of Equity Shareholders	Number of Equity share held	Percentage of holding
Promoters	27,42,015	26.00%
Other Entities of the Promoter Group	78,257	0.74%
Mutual Funds and UTI	-	-



Banks, Financial Institutions, States and Central Government	-	-
Insurance Companies	-	-
Foreign Institutional Investors and Foreign Portfolio Investors – Corporate	6,00,000	0.57%
NRI's / OCB's / Foreign Nationals	29,195	0.28%
Body Corporates (Non-Institutional)	3,34,386	03.17%
Indian Public and Others	72,11,976	68.38%
Clearing Members	90,384	0.86%
Alternate Investment Fund	-	-
IEPF account	-	-
GRAND TOTAL	1,05,46,213	100.00%

C. TOP TEN EQUITY SHAREHOLDERS OF THE COMPANY AS ON MARCH 31, 2023

Sr. No.	Name of the Shareholder	Number of equity shares held	Percentage of holding
1	Atul Arvindbhai Vasani	2262023	21.35
2	Sapan Anil Shah	763929	7.21
3	Nupur Anil Shah	626422	5.91
4	Jagruiti Atul Vasani	479992	4.53
5	Dishant Milanbhai Parikh	402849	3.80
6	Margi Jigneshbhai Shah	248947	2.35
7	Seema Aggarwal.	200000	1.89
8	Amaysha Textiles Private Limited	115159	1.09
9	Varun Krishnavtar Kabra	105000	0.99
10	Kamini K Vora	87400	0.82

10. DEMATERIALIZATION OF SHARES AND LIQUIDITY

The Company's shares are compulsorily traded in dematerialized form on NSE. Equity shares of the Company representing 100 percent of the Company's equity share capital are dematerialized as on March 31, 2023. Under the Depository System, the International Securities Identification Number (ISIN) allotted to the Company's shares is INE972X01014 and Share Warrant is INE972X13019

11. OUTSTANDING GDRS/ADRS/WARRANTS OR ANY CONVERTIBLE INSTRUMENTS, CONVERSION DATE AND LIKELY IMPACT ON EQUITY

Name of Securities	Outstanding Securities	Issue price	Total Amount	Convertible or Non-Convertible Securities	Ratio of conversion	Tenure
Share Warrants	2500000	121.82	304550000	Convertible	1:1	18 Months

12. COMMODITY PRICE RISK OR FOREIGN EXCHANGE RISK AND HEDGING ACTIVITIES

The Company does not deal in commodities and hence the disclosure pursuant to SEBI Circular dated November 15, 2018 is not required to be given. For a detailed discussion on foreign exchange risk and hedging activities, please refer to Management Discussion and Analysis Report.

13. EQUITY SHARES IN THE SUSPENSE ACCOUNT

There are no Equity Shares of the Company in suspense Account. Hence, the requirement of Regulation 34(3) and Part F of Schedule V to the SEBI Listing Regulations is not applicable.

14. CORRESPONDENCE ADDRESS : 706 to 709, 7th Floor, Aravali Business Center,
R. C. Patel Road, Off Sodawala Lane, Borivali (West),
Mumbai – 400092. Maharashtra, India.

15. THE COMPANY OBTAINED CREDIT MSE RATING FROM CRISIL MENTIONED AS BELOW

CRISIL RATING	:	CRISIL SME 3
Financial Strength	:	Good
Operating Performance	:	Corresponds Grading MSE 3 indicates 'Good' level of Creditworthiness, adjudged in relation to other MSEs
Report Date	:	March 28, 2023
Valid Till	:	March 26, 2024

VI. OTHER DISCLOSURES:

1. RELATED PARTY TRANSACTION

Your Company has historically adopted the practice of undertaking related party transactions only in the ordinary and normal course of business and at arm's length as part of its philosophy of adhering to highest ethical standards, transparency, and accountability. In line with the provisions of the Companies Act, 2013 and the Listing Regulations, the Board has approved a policy on related party transactions. The policy on related party transactions has been placed on the Company's website at <https://www.vaishalipharma.com/investors/company-policy/>

Prior omnibus approval of the Audit Committee and the Board is obtained for the transactions which are foreseeable and of a repetitive nature. All related party transactions are placed on a quarterly basis before the Audit Committee and before the Board for review and approval.

All contracts, arrangements and transactions entered by the Company with related parties during financial year 2022-23 were in the ordinary course of business and on an arm's length basis. There were no contracts, arrangements or transactions entered during financial year 2022-23 that fall under the scope of Section 188(1) of the Companies Act, 2013.

2. DETAILS OF NON-COMPLIANCE BY THE COMPANY

The National Stock Exchange of India had imposed fine of Rs.10,000/- on the Company for violation of Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to submission of E-voting results of the EGM held on January 4, 2023 in the prescribed XBRL format. The same has been paid by the Company on February 16, 2023.

3. VIGIL MECHANISM

Pursuant to the provisions of Section 177 (9) & (10) of the Act read with Rule 7 of the Companies (Meeting of Board and its Powers) Rules, 2014, Vigil Mechanism for Directors and employees to report genuine concern and grievances has been established. The said mechanism is governed by the Audit Committee. The details of the policy is available on the website of the company at <https://www.vaishalipharma.com/investors/company-policy/>



4. DETAILS OF COMPLIANCE WITH NON-MANDATORY (DISCRETIONARY) REQUIREMENTS.

The Company has duly fulfilled the following discretionary requirements as prescribed in Sub – Regulation 1 of Regulation 27 read with Part E of Schedule II of the SEBI Listing Regulations as follows:

- There are no audit qualifications during the year under review.
- The Internal auditors report to the Audit Committee every quarter.

The Company has adopted the policy on Determination of Materiality on the material events to stock exchanges in accordance with the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said policy is available on the website of the Company <https://www.vaishalipharma.com/investors/company-policy>

The Company has adopted the policy on preservation of documents in accordance with Regulation 9 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Documents Preservation Policy is available on the website of the Company.

The rest of the Non-Mandatory Requirements will be implemented by the Company as and when required and/or deemed necessary by the Board.

5. WEB LINK WHERE POLICY ON DETERMINING ‘MATERIAL’ SUBSIDIARIES IS DISCLOSED

The Company has formulated a policy pursuant to provisions of Chapter IV of SEBI Listing Regulations to determine material subsidiaries.

The Policy is posted on the website of the Company and the web link for the same is <https://vaishalipharma.com/investors/company-policy/>

6. DISCLOSURE OF COMMODITY PRICE RISKS AND COMMODITY HEDGING ACTIVITIES

The Company is not involved in such activities hence there is no such risk involved.

7. DETAILS OF UTILIZATION OF FUNDS RAISED THROUGH PREFERENTIAL ALLOTMENT OR QUALIFIED INSTITUTIONS PLACEMENT

The Company has realized 25% of 2500000 Share Warrants (upfront money) amounting to Rs. 7,62,61,160/- whereas Mr. Atul Arvind Vasani's 25% amount of Rs. 2,59,47,660/- has been adjusted against his existing debt on February 07, 2023. This fund is utilized for the working Capital of the Company.

8. CERTIFICATE ON CORPORATE GOVERNANCE FROM PRACTICING COMPANY SECRETARIES

The Company has obtained a certificate from the Practicing Company Secretary regarding compliance of conditions of Corporate Governance prescribed under the Listing agreement with Stock Exchange which forms part of this report at **ANNEXURE - 2**.

9. QUALIFICATION / DISQUALIFICATION OF DIRECTORS

None of the Directors of the Company have been debarred or disqualified from being appointed or continuing as directors of companies by the Securities and Exchange Board of India or the Ministry of Corporate Affairs or any such statutory authority. A Certificate to this effect, duly signed by the Practicing Company Secretary is annexed to this Report.

The Company has received a certificate as per **ANNEXURE - 3** from M/s. Disha & Associates, Practicing Company Secretaries confirming that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, Reserve Bank of India or any such statutory authority.

10. INSTANCES OF NOT ACCEPTING ANY RECOMMENDATION OF THE COMMITTEE BY THE BOARD

There were no such instances where the Board had not accepted any recommendation of any committee of the Board, whether mandatorily required or not, in the relevant financial year.

11. REMUNERATION OF AUDITOR

M/s. Raman S. Shah & Associates, Chartered Accountants (Firm Registration No. 119891W) have been re-appointed as the Statutory Auditors of the Company for a period. The particulars of payment of Statutory Auditors' fees for F.Y. 22-23, on consolidated basis is given below:

(₹ in Lakhs)

Particulars	Amount
Services as statutory auditors (including quarterly audits)	1.25
Fees for other audit related services	-
Total	1.25

12. POLICY FOR PREVENTION, PROHIBITION AND REDRESSAL OF SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition, and Redressal) Act, 2013.

The Company has complied with provisions relating to the constitution of an Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013. The Internal Complaints Committee (ICC) has been setup to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, and trainees) are covered under this policy.

The following is the summary of sexual harassment complaints received and disposed of during the year 2022-23.

No. of complained filed	:	NIL
No. of complaints received	:	NIL
No. of complaints disposed off	:	NIL

13. DISCLOSURE BY THE COMPANY AND ITS SUBSIDIARIES OF 'LOANS AND ADVANCES IN THE NATURE OF LOANS TO FIRMS/COMPANIES IN WHICH DIRECTORS ARE INTERESTED BY NAME AND AMOUNT':

The Company have not granted loans and advances in the nature of loans to firms / companies in which directors of the Company are interested.

14. CORPORATE SOCIAL RESPONSIBILITY

In accordance with Section 135 of the Act and Companies (Corporate Social Responsibility Policy) Rules, 2014. The Company is not required to form the committee, whereas Board has granted the approval for the expenditure which Company have to spend according, annexed herewith as **ANNEXURE - D**

15. The company has adopted, the discretionary requirements as specified in Part E of Schedule II related with Corporate Governance, as listed below:.



- a. The Board
- b. Shareholder Rights
- c. Unmodified audit report
- d. Reporting of internal auditor

VII. DISCLOSURE OF COMPLIANCE WITH CORPORATE GOVERNANCE

The Company has complied with the requirements specified in Regulations 17 to 27 and Clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the SEBI Listing Regulations, 2015.

VIII. DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

Aggregate number of shareholders and the outstanding shares in the suspense account : None
lying at the beginning of the year

Number of shareholders to whom shares were transferred from suspense account during : None
the year

number of shareholders to whom shares were transferred from suspense account during : None
the year

aggregate number of shareholders and the outstanding shares in the suspense account : None
lying at the end of the year

Frozen of voting rights on such shares till the rightful owner of such shares claims the : None
shares.

IX. CORPORATE POLICIES

Sr. No.	Particulars	Web link
1	Code of Conduct for Directors & Senior Management	https://vaishalipharma.com/investors/company-policy/
2	Related party transactions	https://vaishalipharma.com/investors/company-policy/
3	Vigil Mechanism Policy	https://vaishalipharma.com/investors/company-policy/
4	Policy on Insider trading	https://vaishalipharma.com/investors/company-policy/
5	Policy for determining material subsidiaries	https://vaishalipharma.com/investors/company-policy/
6	Policy on Determination of Materiality for Disclosures	https://vaishalipharma.com/investors/company-policy/
7	Policy on Archival and Preservation of Documents	https://vaishalipharma.com/investors/company-policy/
8	Reconciliation of Share Capital Audit Report	https://www.vaishalipharma.com/investors/other-filings-with-stock-exchange/
9	Dividend Distribution Policy	Not Applicable
10	Terms of Appointment of Independent Directors	https://vaishalipharma.com/investors/company-policy/
11	Familiarization Program	https://vaishalipharma.com/investors/company-policy/
12	Policy on Preservation Archival of Documents	https://vaishalipharma.com/investors/company-policy/
13	Stock Exchange Intimations	https://www.vaishalipharma.com/investors/other-filings-with-stock-exchange/
14	Policy on Prevention of Sexual Harassment at Workplace	https://vaishalipharma.com/investors/company-policy/
15	Term of Appointment of Independent Director	https://vaishalipharma.com/investors/company-policy/

16	Criteria For Making Payments to Non-Executive Directors	https://vaishalipharma.com/investors/company-policy/
17	Policy on Archival & Presentation of Documents	https://vaishalipharma.com/investors/company-policy/
18	Disclosure of commodity price risk and commodity hedging	Not Applicable
19	Disclosure of utilization of funds raised through preferential allotment	Not Applicable
20	Dividend Distribution Policy	Not Applicable
21	Determining Material Subsidiaries	https://vaishalipharma.com/investors/company-policy/

Date: September 05, 2023**Place: Mumbai****For Vaishali Pharma Limited****Sd/-****Atul Vasani****Chairman & Managing Director****DIN:- 02107085**



ANNEXURE - D

ANNUAL REPORT ON CSR ACTIVITIES

1. BRIEF OUTLINE ON CSR POLICY OF THE COMPANY:

The company is currently in its initial stages of implementing CSR projects. Our vision revolves around actively contributing to the betterment of the communities and environment in which we operate through our initiatives, services, and ethical conduct, we strive to support sustainable societal and communal growth as a responsible organization.

At present, our CSR efforts involve channeling funds to the Prime Minister's National Relief Fund. As our CSR commitments mature, we will establish a dedicated CSR Committee to more effectively address community needs. This approach ensures the delivery of significant value to the societies we are committed to serving.

2. CSR Committee: **Not Applicable**

3. The web-link of CSR Policy and CSR projects approved by the Board is disclosed on the website of the company: <https://www.vaishalipharma.com/investors/company-policy/>

4. The details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report): **Not Applicable**

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any- **Not Applicable**

6. Average net profit of the company for last three Financial Years: **239.14 Lakhs**

7. (a) Two percent of average net profit of the company: **4.78 Lakhs**

(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years – **Nil**

(c) Amount required to be set off for the financial year, if any: **Nil**

(d) Total CSR obligation for the financial year (7a+7b- 7c): **4.78 Lakhs**

(e) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year (Amount in Lakhs)	Amount Unspent				
	Total Amount transferred to Unspent CSR Account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
	Amount	Date of Transfer	Name of the fund	Amount	Date of Transfer
Nil	Not Applicable	Not Applicable	Prime Ministers National Relief Fund	2 lakhs	August 31, 2023
				2.78 Lakhs	September 01, 2023

(b) Details of CSR amount spent against ongoing projects for the financial year: **Not Applicable, The Company does not have any ongoing projects as defined under CSR Rules**

8. (a) Details of Unspent CSR amount for the preceding three financial years: **4.78 Lakh**

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):
Not Applicable

Date: September 05, 2023
Place: Mumbai

For Vaishali Pharma Limited
Sd/-
Atul Vasani
Chairman & Managing Director
DIN:- 02107085



ANNEXURE - E

DETAILS PERTAINING TO REMUNERATION AS REQUIRED UNDER SECTION 197(12) OF THE COMPANIES ACT, 2013 READ WITH RULE 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

- (i) The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2022-23 and ratio of the remuneration of each Director to the median remuneration of the employee of the Company for the financial year 2022-23 are as under:

Name of the Director	Designation	Remuneration In FY 2022-23	% increase in Remuneration in FY 2022-23	Ratio of remuneration of each director to median remuneration of employees
Mr. Atul Vasani	Managing Director	54,00,000	0%	20.59 : 1
Mrs. Jagruti Vasani	Whole Time Director	12,00,000	0%	4.58 : 1
Mr. Dewansh Ajay Vasani	Executive Director	12,00,000	0%	4.58:1
Mr. Ashvin Ganatra	Independent Director	-	-	-
Mr. Manish Ved	Independent Director	-	-	-
Mr. Pratik Jakhelia	Independent Director	-	-	-
Mr. Hemant Pathak	Chief Executive Officer	-	-	-
Mr. Ratnesh Singh	Chief Financial Officer	9,01,200	0%	3.44 : 1
Ms. Vishwa Mekhia	Company Secretary & Compliance Officer	4,68,151	0%	1.79:1

- The median remuneration of employees of the Company during the financial year was **Rs. 2,62,226/-**
 - Percentage decrease in the median remuneration of employees in the financial year 2022-23: **0.40%**
 - Number of permanent employees on the rolls of Company: **27 Employee**
 - Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration: The average percentile increase in the salaries of employees other than the managerial personnel in the financial year 2022-23 is **NIL** whereas the percentile increase in the managerial remuneration during the year is **NIL**.
 - The key parameters for any variable component of remuneration availed by the directors: **NIL**
 - It is hereby affirmed that the remuneration paid is as per the Remuneration Policy for Directors, Key Managerial Personnel and other Employees.
- (ii) Information as per Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:
- Employees of Company, who were employed throughout the financial year, were in receipt of remuneration for that year which, in the aggregate, was not less than One Crore Two Lakhs Rupees: **NIL**

- Employees of Company, who were employed for a part of the financial year, were in receipt of remuneration for any part of that year, at a rate which, in the aggregate, was not less than Eight Lakh and Fifty Thousand Rupees per month: **NIL**
- Employees who were employed throughout the financial year or part thereof, was in receipt of remuneration in that year which, in the aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company: **NIL**
- The particulars of employees posted and working in a country outside India, not being Directors or their relatives, drawing more than sixty lakh rupees per financial year or five lakh rupees per month, as the case may be, as may be decided by the Board – **NIL**.

Date: September 05, 2023
Place: Mumbai

For Vaishali Pharma Limited

Sd/-	Sd/-
Atul Vasani	Jagruti Vasani
Chairman &	Whole Time
Managing Director	Director
DIN:- 02107085	DIN:-02107094



MANAGEMENT DISCUSSION AND ANALYSIS

[Pursuant to Regulation 34 (2) (e) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

1. INDUSTRY STRUCTURE & DEVELOPMENTS

Vaishali Pharma is a dynamic player in the pharmaceutical sector, specializing in Active Pharmaceutical Ingredients, pharmaceutical formulations, surgical products, Herbal & Nutraceutical Products, and veterinary supplements, catering to both domestic and international markets.

Our company's growth trajectory is intertwined with our ability to introduce cutting-edge pharmaceutical solutions not only in India but also across global markets.

2. EMERGING PROSPECTS AND CHALLENGES

The sophisticated technology underpinning our offerings acts as a formidable entry barrier, reducing the likelihood of intense rivalry. Nevertheless, the constraint of a relatively smaller market size warrants consideration.

Our distinct market advantage stems from our steadfast commitment to delivering products of superior quality within stipulated timelines. Over the years, we have fostered enduring partnerships with clients and suppliers, reinforcing our market standing. Our true strength lies in our dedicated workforce, a priceless asset that propels our success.

3. SEGMENT-WISE OR PRODUCT-WISE PERFORMANCE

The business of the company is trading (including exports) of pharmaceuticals products. During the financial year 2022-23, revenue from operation is Rs. 6,966.28 Lakhs

4. OUTLOOK

Looking ahead, our focus is on building a sustainable future for our company, our stakeholders, and the planet. We believe that sustainability is the key to long-term success and we are committed to integrating it into every aspect of our operations.

We understand the importance of good governance and we will continue to uphold the highest standards of ethical conduct, transparency, and accountability in all our dealings.

We are confident that with strong focus on sustainability, innovation, and good governance, Vaishali Pharma Limited is well-positioned to achieve sustainable growth and create long-term value for all our stakeholders.

The Company is continuously working on strengthening the business. The Company has been successfully executing major orders from various customers and it has been enjoying the confidence of all customers with repeat orders. The Company has been making consistent efforts for improving margins in majority products by reducing the various costs. The results of these initiatives are expected to improve the overall profitability of the Company further during the coming years.

5. MITIGATING RISKS AND ADDRESSING CONCERNS

Risk, whether realized or potential, has the power to disrupt our strategic course or objectives. In the global pharmaceutical landscape, characterized by its inherent complexities, threats such as product integrity issues, intellectual property entanglements, regulatory non-compliance, exchange rate volatility, and unscrupulous marketing practices loom large. Such challenges can result in penalties, brand erosion, revenue setbacks, and product recalls.

While achieving complete risk elimination is an unrealistic aspiration, our unwavering commitment is to meticulously evaluate their possible impact, adapt to changing risk dynamics, and devise proactive measures to alleviate their adverse repercussions.

As we forge ahead, we remain steadfast in our mission to navigate the pharmaceutical landscape with resilience and innovation, while embracing the responsibilities of risk management and strategic adaptation.

6. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has strong and adequate internal control system suitable to its size and nature of business. The internal audit is done by an independent firm of Chartered Accountants. Internal audits are regularly carried out to review the internal control systems. The systems ensure protection of assets and proper recording of transactions. The internal audit reports along with recommendations contained therein are reviewed by the Audit Committee of the Board. It is a regular practice to review the same by the Audit Committee.

7. DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

During the year under review, the operating revenue including other income of the Company is Rs. 7189.15 Lakhs for current year as compared to Rs. 7760.89 Lakhs in previous year. Your Directors are hopeful to improve the growth rate in turnover. The Company generated funds of Rs. 884.53 Lakhs as compared to Rs. 572.84 Lakhs in previous year.

8. MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONTS, INCLUDING NUMBER OF PEOPLE EMPLOYED

The Company had cordial relations with its employees and all problems were solved across the table in a very congenial atmosphere. Your Directors wish to place on record their appreciation to all its employees for their sustained efforts and valuable contribution.

9. DETAILS OF SIGNIFICANT CHANGES IN KEY FINANCIAL RATIOS, ALONG WITH DETAILED EXPLANATIONS THEREOF (I.E. CHANGE OF 25% OR MORE AS COMPARED TO THE IMMEDIATELY PREVIOUS FINANCIAL YEAR)

1.	Debtors Turnover	: 1.24
2.	Inventory Turnover	: 29.72
3.	Interest Coverage Ratio	: 5.4
4.	Current Ratio	: 2.27
5.	Debt Equity Ratio	: 0.34
6.	Operating Profit Margin	: 0.15
7.	Net Profit Margin or sector-specific equivalent ratios, as applicable	: 0.092

Nil impact of Bad Debts written off

The following significant changes in key financial ratios was recorded:

- The Debtors Turnover Ratio significantly increase to 1.24;
- The Inventory Turnover Ratio significantly decrease to 29.72;
- The Interest Coverage Ratio significantly increase to 5.40;
- The Current Ratio significantly decrease to 2.27;
- The Debt Equity Ratio significantly decrease to 0.34;
- The Net Profit Margin or Sector – Specific equivalent ratios increased to 0.092

Apart from above there is no changes in other Key Financial Ratios



10. VARIATION IN NET WORTH

The Return on Net Worth in current year is 0.63 and in the previous year was 0.38. During the period under review, the Return on Net Worth significantly increased to 0.63, Due to profit the Companies Net Worth has increased to 0.63.

11. CAUTIONARY STATEMENT

Statements in the management discussion analysis describing the Company's objectives, projections, estimates, expectations are forward looking within the meaning of applicable security-laws and regulations. Forward-looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. Actual results may differ materially from these expressed in the statement. Important factors that could make difference to Company's operations include economic conditions, changes in the Government priorities/policies/ regulations, tax laws and other statutes and other incidental factors affecting the business environment. The Company assumes no responsibility to publicly amend, modify or revise forward-looking statements on the basis of any subsequent developments, information or events.

Date: September 05, 2023
Place: Mumbai

For Vaishali Pharma Limited

Sd/-
Atul Vasani
Chairman &
Managing Director
DIN:- 02107085

Sd/-
Jagruti Vasani
Whole Time
Director
DIN:-02107094

ANNEXURE - 1

**DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR
MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT**

This is to confirm that the Company has adopted a Code of Conduct for its employees including the Managing Director, Executive Directors, Non-Executive Directors and Independent Directors. These Codes are available on the Company's website.

I, confirm that the Company has in respect of the year ended March 31, 2023, received from the Senior Management Team of the Company and the Members of the Board a declaration of compliance with the Code of Conduct as applicable to them.

For the purpose of this declaration, Senior Management Team means the Chief Financial Officer, Chief Executive Officer, Chief Operating Officer, Company Secretary as on March 31, 2023.

For Vaishali Pharma Limited

Sd/-
Hemant Pathak
CEO



ANNEXURE – 2

CERTIFICATE ON CORPORATE GOVERNANCE COMPLIANCE

To the Members

Vaishali Pharma Limited

CIN: L52310MH2008PLC181632

This report contains details of compliance of conditions of Corporate Governance by Vaishali Pharma Limited ('the Company') for the year ended March 31, 2023 as stipulated in regulations 17-27, clause (b) to (i) of regulation 46 (2) and paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations') pursuant to the Listing Agreement of the Company with Stock Exchanges.

Management's Responsibility for compliance with the conditions of Listing Regulations

The compliance with the terms and conditions contained in the corporate governance is the responsibility of the Management of the Company including the preparation and maintenance of all relevant supporting records and documents.

Auditor's Responsibility

My examination was limited to procedures and implementation thereof adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

Pursuant to the requirements of the Listing Regulations, it is my responsibility to provide a reasonable assurance whether the Company has complied with the conditions of Corporate Governance as stipulated in the Listing Regulations for the year ended March 31, 2023.

Opinion

In my opinion, and to the best of my information and according to explanations given to me, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Regulations.

I, further, state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

Restriction on use

The certificate is addressed and provided to the members of the Company solely for the purpose to enable the Company to comply with the requirement of the Listing Regulations and it should not be used by any other person or for any other purpose.

Accordingly, I do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without my prior consent in writing.

For **M/s. Disha & Associates,**

sd/-

Disha Shah

Practicing Company Secretary

Proprietor

Membership No: A34831/ COP No: 22710

UDIN: A034831E000947545

Date: September 05, 2023

Place: Mumbai

ANNEXURE – 3

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

Vaishali Pharma Limited
CIN: L52310MH2008PLC181632

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Vaishali Pharma Limited** having registered office at 706 to 709, 7th Floor, Aravali Busines Center, R. C. Patel Road, Off Sodawala Lane, Borivali West Mumbai-400092 (hereinafter referred to as “the Company”), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal (www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on March 31, 2023 have been disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India and Ministry of Corporate Affairs.

Sr. No.	Name of Director	DIN	Original Date of Appointment	Date of Cessation
1.	Atul Arvind Vasani	02107085	25/04/2008	-
2.	Jagruti Atul Vasani	02107094	12/11/2009	-
3.	Dewansh Ajay Vasani	08111804	26/04/2018	-
4.	Ashvin Jamnadas Ganatra	08653815	31/12/2019	-
5.	Manish Bhagwandas Ved	08654674	31/12/2019	-
6.	Pratik Vikram Jakhelia	07726752	10/07/2021	-

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. My responsibility is to express an opinion on these based on my verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **M/s. Disha & Associates,**

Sd/-

Disha Shah

Practicing Company Secretary

Proprietor

Membership No: A34831/ COP No: 22710

UDIN: A034831E000947666

Date: September 05, 2023

Place: Mumbai



Independent Auditor's Report

**To the Members of
Vaishali Pharma Limited**

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **Vaishali Pharma Limited** ("the Company"), which comprise the balance sheet as at 31 March 2023, and the statement of profit and loss (including other comprehensive income), statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2023, and profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to report that fact. We have nothing to report in this regards. Further we also have except as explained in Note 12 to the accompanying statement, the company has a current assets of trade receivables Rs. 5,361.01 Lakh [previous year Rs. 5,850.54 Lakh] and Note 8B to the accompanying statement, the company has a current assets of deposit, loans & advances Rs. 1,143.89 Lakh [previous year Rs. 1,186.04 Lakh] recoverable from various customers and recipients. The trade receivable having Rs. 2618.58 Lakh, receivable from more than 3 years, that a material uncertainty exists as at 31 March 2023 for possible recovery of the trade receivables and deposit, loans & advances. In the absence of adequate and appropriate evidence for such receivables and management assessment, we are unable to obtain sufficient appropriate audit evidence to comment on adjustment, if any, that may further be required to be made to the carrying value of the above mention trade receivables of Rs. 5,361.01 Lakh and deposit, loans & advances Rs. 1,143.89 Lakh as at 31 March 2023 and the consequential impact thereof on the accompanying Statement.

Management's Responsibility for the Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the state of affairs, profit and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.
- Conclude on the appropriateness of management's and Board of Directors' use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2020 ("the Order") issued by the Central Government in terms of section 143 (11) of the Act, we give in the "**Annexure A**" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. (A) As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The balance sheet, the statement of profit and loss (including other comprehensive income), the statement of changes in equity and the statement of cash flows dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under section 133 of the Act.
 - e) On the basis of the written representations received from the directors as on 31 March 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2023 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in **“Annexure B”**.
- (B) With respect to the other matters to be included in the Auditors’ Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- a) The company has no pending litigation as at 31 March 2023, hence its financial position is not affected;
 - b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company; and
 - d) The Management has represented that, to the best of its knowledge and belief, other than disclosed in the notes, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - e) The Management has represented that, to the best of its knowledge and belief, other than disclosed in the notes to accounts, no funds have been received by the Company from any person or entity, including foreign entity (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;



- f) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

(C) With respect to the matter to be included in the Auditors' Report under section 197(16):

In our opinion and according to the information and explanations given to us, the remuneration paid by the company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us.

For Raman S. Shah & Associates
Chartered Accountants
Firm's Registration No.: 119891W

Sd/-

Santosh A. Sankhe
Partner
Membership No.: 100976

UDIN:- 23100976BGXEMJ6691

Place: Mumbai
Date: 22nd May 2023

Annexure A to the Independent Auditors' Report

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

With reference to the Annexure A referred to in the Independent Auditors' Report to the members of the Company on the standalone financial statements for the year ended 31 March 2023, we report the following:

- i) In respect of the Company's Property, Plant & Equipment
 - (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangibles assets.
 - (b) All fixed assets have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
 - (c) The title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the financial statements are held in the name of the company.
 - (d) The Company has not revalued its Property, Plant and Equipment (including Right of use assets) or intangible assets during the year ended March 31, 2023.
 - (e) There are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- ii)
 - (a) The management has conducted physical verification of inventory at reasonable intervals during the year. In our opinion the coverage and the procedure of such verification by the management is appropriate. No discrepancies of 10% or more in aggregate for each class of inventory were noticed on such physical verification.
 - (b) During any point of time of the year, the company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks are in agreement with the books of account of the Company.
- iii)
 - (a) During the year the company has not provided loans or provided advances in the nature of loans, or stood guarantee, or provided security to any other entity.



- (b) During the year the investments made, guarantees provided, security given and the terms and conditions of the grant of all loans and advances in the nature of loans and guarantees to companies are not prejudicial to the Company's interest.
 - (c) in respect of loans and advances in the nature of loans, company has not granted loans and advances in the nature of loans. Accordingly, the requirement to report on clause 3(iii)(c) of the Order is not applicable to the Company.
 - (d) There are no amounts of loans and advances in the nature of loans granted to companies, firms, limited liability partnerships or any other parties which are overdue for more than ninety days. Accordingly, the requirement to report on clause 3(iii)(d) of the Order is not applicable to the Company.
 - (e) The Company had not granted loans to companies which had fallen due during the year. Accordingly, the requirement to report on clause 3(iii)(d) of the Order is not applicable to the Company.
 - (f) The Company has not granted any loans or advances in the nature of loans, either repayable on demand or without specifying any terms or period of repayment to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(f) of the Order is not applicable to the Company.
- iv)** There are no loans, investments, guarantees, and security in respect of which provisions of sections 185 and 186 of the Companies Act, 2013 are applicable and accordingly, the requirement to report on clause 3(iv) of the Order is not applicable to the Company.
- v)** The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- vi)** The company is in business of trading of pharmaceutical products, maintenance of cost records as required under sub section 1 of section 148 of the Companies Act, 2013 not applicable to the company. Accordingly, the requirement to report on clause 3(vi) of the Order is not applicable to the Company.
- vii)**
- (a) The Company is generally been regular in depositing with appropriate authorities undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it. According to the information and explanations given to us and based on audit procedures performed by us, no undisputed amounts payable in respect of these statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.

- (b) There is no dues of goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of custom, duty of excise, value added tax, cess, and other statutory dues which have not been deposited on account of any dispute.

viii) The Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.

ix)

- (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
- (c) Term loans were applied for the purpose for which the loans were obtained.
- (d) On an overall examination of the standalone financial statements of the Company, the Company has not used funds raised on short-term basis in the form of short-term loans, cash credits from Banks, commercial papers, Inter Corporate Deposits and other financial liabilities for long-term purposes.
- (e) The company does not have any subsidiaries, associates or joint ventures. Accordingly, the requirement to report on clause 3(ix)(e) of the Order is not applicable to the Company.
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Hence, the requirement to report on clause (ix)(f) of the Order is not applicable to the Company.

x)

- (a) The Company has not raised any money during the year by way of initial public offer / further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.
- (b) The Company has not made any preferential allotment or private placement of shares /fully or partially or optionally convertible debentures during the year under audit and hence, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company.

xi)

- (a) No fraud by the Company or no fraud on the Company has been noticed or reported during the year.
- (b) According to the information available, the requirement to report on clause 3(xi)(b) of the Order is not applicable to the Company.



- (c) According to the information available, the requirement to report on clause 3(xi)(c) of the Order is not applicable to the Company.
- xii)**
- (a) The Company is not a nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a), (b) and (c) of the Order are not applicable to the Company.
- xiii)** Transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the standalone financial statements, as required by the applicable accounting standards
- xiv)** According to the information the requirement to report on clause 3(xiv)(a) and (b) of the Order are not applicable to the Company.
- xv)** The Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence requirement to report on clause 3(xv) of the Order is not applicable to the Company.
- xvi)**
- (a) The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi)(a) of the Order is not applicable to the Company.
- (b) The Company has not conducted any Non-Banking Financial or Housing Finance activities without obtained a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.
- (c) The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi)(c) of the Order is not applicable to the Company.
- (d) As per the information available, the requirement to report on clause 3(xvi)(d) of the Order is not applicable to the Company.
- xvii)** The Company has not incurred cash losses in the current year and in the immediately preceding financial year respectively
- xviii)** There has been no resignation of the statutory auditors during the year and accordingly requirement to report on Clause 3(xviii) of the Order is not applicable to the Company.
- xix)** On the basis of the financial ratios available, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We

further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- xx)** As per the information available, the requirement to report on clause 3(xx)(a) and (b) of the Order are not applicable to the Company.

For Raman S. Shah & Associates
Chartered Accountants
Firm's Registration No.: 119891W

Sd/-

Santosh A. Sankhe
Partner
Membership No.: 100976

UDIN:- 23100976BGXEMJ6691

Place: Mumbai
Date: 22nd May 2023



Annexure B to the Independent Auditors' Report – 31 March 2023

Report on the internal financial controls with reference to the aforesaid financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

(Referred to in paragraph 2(A)(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of **Vaishali Pharma Limited** ("the Company") as of 31 March 2023 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, an adequate internal financial controls with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at 31 March 2023, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable, to an audit of internal financial controls both applicable to an audit of Internal Financial Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's

judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For Raman S. Shah & Associates
Chartered Accountants
Firm's Registration No.: 119891W

Sd/-

Santosh A. Sankhe
Partner
Membership No.: 100976

UDIN:- 23100976BGXEMJ6691

Place: Mumbai
Date: 22nd May 2023



Balance Sheet as at March 31, 2023

(₹ in Lakhs)

Particulars	Note No.	As at March 31, 2023	As at March 31, 2022
I ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment	4	80.26	85.80
(b) Right of Use Assets	5	99.53	4.56
(c) Intangible assets	6	18.40	27.68
(d) Intangible assets under development		67.21	49.24
(e) Financial assets			
(i) Investments			
(a) Other investments	7	43.15	43.15
(ii) Other financial assets	8A	228.06	221.80
(f) Deferred tax asset (net)	9C	14.34	16.07
(g) Other non - current assets	10A	71.73	71.26
Total non-current assets		622.68	519.56
2 Current assets			
(a) Inventories	11	305.01	62.90
(b) Financial assets			
(i) Trade receivables	12	5,361.01	5,850.54
(ii) Cash and cash equivalents	13	52.92	116.23
(iii) Bank balances other than (ii) above	14	45.56	19.30
(iv) Other financial assets	8B	1,143.89	1,186.04
(c) Other current assets	10B	358.73	407.84
Total current assets		7,267.12	7,642.85
Total Assets		7,889.80	8,162.40
II EQUITY AND LIABILITIES			
1 EQUITY			
(a) Share capital	15	1,054.62	1,054.62
(b) Other equity		2,998.57	1,580.80
Equity attributable to the owners of the Company		4,053.19	2,635.42
2 LIABILITIES			
2a Non-current liabilities			
(a) Financial Liabilities			
(i) Borrowings	16A	522.68	310.62
(ii) Lease Liabilities	17	88.22	3.75
(b) Provisions	18A	18.92	18.91
Total non-current liabilities		629.82	333.29
2b Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	16B	843.66	1,765.59
(ii) Lease Liabilities	17	19.06	1.17
(iii) Trade payables	19		
- Total outstanding dues of Micro, Small and Medium Enterprises		61.52	161.44
- Total outstanding dues of creditors other than Micro, Small and Medium Enterprises		1,738.15	2,676.63
(iv) Other financial liabilities	20	33.97	56.39
(b) Provisions	18B	2.41	3.49
(c) Income Tax Liabilities (Net)		194.61	127.17
(d) Other current liabilities	21	313.40	401.81
Total current liabilities		3,206.78	5,193.69
Total Equity and Liabilities		7,889.80	8,162.40

Significant Accounting Policies

3

The notes are an integral part of these financial statements

As per our report of even date attached

For Raman S. Shah & Associates

Chartered Accountants

Firm Registration No. 119891W

Sd/-

Santosh A. Sankhe

Partner

Membership No. 100976

Mumbai, May 22, 2023

For and on behalf of the Board

Vaishali Pharma Limited

CIN : L52310MH2008PLC181632

Sd/-

Atul Arvind Vasani

Chairman & Mg. Director
(DIN:02107085)

Sd/-

Jagruti Atul Vasani

Whole-time Director
(DIN:02107094)

Sd/-

Ratnesh Singh

Chief Financial Officer

Sd/-

Vishwa Mekhia

Company Secretary &
Compliance Officer

Mumbai, May 22, 2023



Statement of Profit and Loss for the year ended March 31, 2023

(₹ in Lakhs)

	Note	Year ended March 31, 2023	Year ended March 31, 2022
I Revenue from operations	22	6,966.28	7,582.08
II Other income	23	222.87	178.81
III Total Income (I + II)		7,189.15	7,760.89
IV Expenses			
(a) Purchases of stock-in-trade		5,709.87	6,354.13
(b) Changes in inventories of finished goods, stock-in-trade and work-in progress	24	(242.11)	(4.07)
(c) Employee benefits expense	25	208.08	209.92
(d) Finance costs	26	200.85	245.88
(e) Depreciation and amortisation expense	27	50.44	45.63
(f) Other expenses	28	377.40	336.57
Total expenses		6,304.53	7,188.06
V Profit before tax (III - IV)		884.62	572.84
VI Tax expense			
Current tax		215.74	145.48
Adjustment of tax relating to earlier periods		8.10	26.81
Deferred tax (credit) / charge		0.43	(1.82)
VII Profit/ (Loss) for the year (V - VI)		660.35	402.37
VIII Other Comprehensive Income			
(i) Items that will not be reclassified to profit or loss			
(a) Remeasurements of the defined benefit plans : (Losses)/ Gains		5.20	2.20
(b) Income tax relating to items that will not be reclassified to profit or loss -(Debit)/ Credit		(1.31)	(0.55)
Other Comprehensive Income for the year (VIII)		3.89	1.65
IX Total Comprehensive Income for the year (VII + VIII)		664.24	404.02
X Earnings per equity share (for continuing operations):			
Equity share of par value of Rs.10/- each			
Basic		6.26	3.82
Diluted	31	5.91	3.82

The notes are an integral part of these financial statements

As per our report of even date attached

For Raman S. Shah & Associates

Chartered Accountants

Firm Registration No. 119891W

Sd/-

Santosh A. Sankhe

Partner

Membership No. 100976

Mumbai, May 22, 2023

For and on behalf of the
Board

Vaishali Pharma Limited

CIN : L52310MH2008PLC181632

Sd/-

Atul Arvind Vasani

Chairman & Mg. Director
(DIN:02107085)

Sd/-

Jagruti Atul Vasani

Whole-time Director
(DIN:02107094)

Sd/-

Ratnesh Singh

Chief Financial Officer

Sd/-

Vishwa Mekhia

Company Secretary &
Compliance Officer

Mumbai, May 22, 2023

Statement of changes in equity for the year ended March 31, 2023

A Equity share capital					
Balance as at March 31, 2021					105,462,130
Changes in equity share capital during the year					-
Balance as at March 31, 2022					105,462,130
Changes in equity share capital during the year					-
Balance as at March 31, 2023					105,462,130

	Reserves and Surplus			Items of OCI	(₹ in Lakhs)
	Share Application Money	Securities Premium Reserve	Retained Earnings	Remeasurement of Defined benefit plan	Total Other Equity
B Other equity					
Balance as at March 31, 2021	-	820.21	356.52	10.51	1,187.24
Profit for the year		-	402.36	-	402.36
Other comprehensive income		-	-	1.65	1.65
Total Comprehensive Income		-	402.36	1.65	404.01
Share issue expenses		(10.45)	-	-	(10.45)
Balance as at March 31, 2022	-	809.76	758.88	12.15	1,580.80
Profit for the year		-	660.35	-	660.35
Other comprehensive income		-	-	3.89	3.89
Total Comprehensive Income		-	660.35	3.89	664.24
Share Warrant	762.61				762.61
Share issue expenses	(6.59)	(2.50)	-	-	(9.09)
Balance as at March 31, 2023	756.03	807.26	1,419.23	16.05	2,998.57

The notes are an integral part of these financial statements

As per our report of even date attached

For Raman S. Shah & Associates

Chartered Accountants

Firm Registration No. 119891W

Sd/-

Santosh A. Sankhe

Partner

Membership No. 100976

For and on behalf of the Board

Vaishali Pharma Limited

CIN : L52310MH2008PLC181632

Sd/-

Atul Arvind Vasani

Chairman & Mg. Director
(DIN:02107085)

Sd/-

Jagruti Atul Vasani

Whole-time Director
(DIN:02107094)

Sd/-

Ratnesh Singh

Chief Financial Officer

Sd/-

Vishwa Mekhia

Company Secretary &
Compliance Officer

Mumbai, May 22, 2023

Mumbai, May 22, 2023



Statement of cash flows for the year ended March 31, 2023

(₹ in Lakhs)

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Cash flows from operating activities		
Profit for the year (before tax)	884.62	572.84
Adjustments for:		
Finance costs recognised in profit and loss	200.85	245.88
Sundry balances written back	(9.78)	-
Interest income recognised in profit and loss	(125.50)	(129.75)
Dividend income	(0.00)	(0.00)
Depreciation and amortisation of non-current assets	50.44	45.63
Operating profit before working capital changes	1,000.63	734.60
<u>Movements in working capital:</u>		
(Increase)/Decrease in trade receivables	489.53	822.53
(Increase)/Decrease in inventories	(242.11)	(4.07)
(Increase)/Decrease in other current and non-current financial assets	103.47	113.64
(Increase)/Decrease in other current and non-current assets	48.64	(222.93)
Increase/(Decrease) in trade payables	(1,028.62)	(1,215.59)
Increase/(Decrease) in provisions, current and non-current liabilities	(107.18)	(13.53)
Cash generated from operations	264.36	214.64
Less: Income taxes paid	(156.40)	(82.78)
Net cash generated from operating activities (A)	107.96	131.86
Cash flows from investing activities		
Purchase of PPE and intangible assets	(29.72)	(86.48)
Interest received	57.93	1.80
Dividend from non-current investments	0.00	0.00
Net cash generated from / (used in) investing activities (B)	28.21	(84.68)
Cash flows from financing activities		
Proceeds/(Payments) from non-current borrowings net	225.27	(188.19)
Proceeds/(Payments) from short-term borrowing net	(675.67)	506.99
Proceeds from issue of share warrants	503.14	
Share Issue expenses	(9.09)	(10.45)
Repayment of Lease Liabilities	(27.99)	(22.64)
Finance cost paid	(188.89)	(243.97)
Net cash used in financing activities (C)	(173.23)	41.75
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(37.06)	88.93
Cash and cash equivalents at the beginning of the year	135.53	46.60
Cash and cash equivalents at the end of the year (Refer note 13 & 14)	98.47	135.53

The notes are an integral part of these financial statements

As per our report of even date attached

For Raman S. Shah & Associates

Chartered Accountants

Firm Registration No. 119891W

Sd/-

Santosh A. Sankhe

Partner

Membership No. 100976

For and on behalf of the Board

Vaishali Pharma Limited

CIN : L52310MH2008PLC181632

Sd/-

Atul Arvind Vasani

Chairman & Mg. Director
(DIN:02107085)

Sd/-

Jagruti Atul Vasani

Whole-time Director
(DIN:02107094)

Sd/-

Ratnesh Singh

Chief Financial Officer

Sd/-

Vishwa Mekhia

Company Secretary &
Compliance Officer

Mumbai, May 22, 2023

Mumbai, May 22, 2023

Notes on standalone financial statements for the year ended March 31, 2023

1. Background

Vaishali Pharma Limited ("the Company") is a public limited company domiciled in India and incorporated on 25th April, 2008 under the provisions of the Companies Act, 1956. The Company is primarily engaged in the marketing of pharmaceutical products including active pharmaceutical ingredients.

The company was listed on 22 August 2017 in NSE – Emerge (SME) and then got migrated to Mainboard of National Stock Exchange on 15th January 2020.

2. Basis of preparation

2.1. Statement of compliance with Ind AS

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.

The Company had prepared its financial statements in accordance with the Accounting Standards notified under Section 133 of the Companies Act, 2013 read together with the Companies (Accounts) Rules 2014 (referred as "Indian GAAP"). The Company's annual financial statements are prepared complying in all material respects with the Ind AS notified under Section 133 of the Companies Act, 2013.

2.2. Overall consideration

The standalone financial statements have been prepared on going concern basis. The accounting policies are applied consistently to all the periods presented in the financial statements. These financial statements are prepared under the historical cost convention unless otherwise indicated.

The standalone financial statement has been prepared considering all Ind AS notified by MCA till reporting date i.e. March 31, 2023. The significant accounting policies used in preparing the financial statements are set out in note 3 of the notes to the standalone financial statement.

2.3. Functional and presentation of currency

The financial statements are prepared in Indian Rupees which is also the Company's functional currency.

2.4. Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal market or the most advantageous market must be accessible to the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.



A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy based on the lowest level input that is significant to the fair value measurement as a whole. The fair value hierarchy is described as below:

Level 1 – Unadjusted quoted price in active markets for identical assets and liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 – unobservable inputs for the asset or liability

For assets and liabilities that are recognised in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of fair value hierarchy.

Fair values have been determined for measurement and / or disclosure purpose using methods as prescribed in "Ind AS 113 Fair Value Measurement".

2.5. Use of significant accounting estimates, judgements and assumptions

The preparation of these financial statements in conformity with the recognition and measurement principles of Ind AS requires management to make estimates and assumptions that affect the reported balances of assets and liabilities, disclosure of contingent liabilities as on the date of financial statements and reported amounts of income and expenses for the periods presented. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and future periods are affected.

Key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Significant estimates and critical judgement in applying these accounting policies are described below:

i) Impairment of financial assets

The impairment provisions for financial assets are based on assumptions about risk of default and expected loss rates. The Company uses judgement in making these assumptions and selecting the inputs to the impairment calculation based on industry practice, Company's past history and existing market conditions as well as forward looking estimates at the end of each reporting period.

ii) Contingencies

Management judgement is required for estimating the possible outflow of resources, if any, in respect of contingencies / claim / litigations against the Company as it is not possible to predict the outcome of pending matters with accuracy.

iii) Income taxes

Provision for tax liabilities require judgements on the interpretation of tax legislation, developments in case law and the potential outcomes of tax audits and appeals which may be subject to significant uncertainty. Therefore, the actual results may vary from expectations resulting in adjustments to provisions, the valuation of deferred tax assets, cash tax settlements and therefore the tax charge in the statement of profit and loss.

iv) Measurement of defined benefit plan & other long term benefits

The cost of the defined benefit gratuity plan / other long term benefits and the present value of the gratuity obligation / other long term benefits are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation / other long term benefits is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

v) Impairment of non-financial assets

The carrying amounts of assets are reviewed at each balance sheet date for any indication of impairment based on internal / external factors. An impairment loss is recognised wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the higher of a) fair value of assets less cost of disposal and b) its value in use. Value in use is the present value of future cash flows expected to derive from an assets or Cash-Generating Unit (CGU).

vi) Leases

Ind AS 116 defines a lease term as the non-cancellable period for which the lessee has the right to use an underlying asset including optional periods, when an entity is reasonably certain to exercise an option to extend (or not to terminate) a lease. The Company considers all relevant facts and circumstances that create an economic incentive for the lessee to exercise the option when determining the lease term. The option to extend the lease term is included in the lease term, if it is reasonably certain that the lessee would exercise the option. The Company reassesses the option when significant events or changes in circumstances occur that are within the control of the lessee.

Based on the assessment done at each balance sheet date, recognised impairment loss is further provided or reversed depending on changes in circumstances. After recognition of impairment loss or reversal of impairment loss as applicable, the depreciation charge for the asset is adjusted in future periods to allocate the asset's revised carrying amount, less its residual value (if any), on a systematic basis over its remaining useful life. If the conditions leading to recognition of impairment losses no longer exist or have decreased, impairment losses recognised are reversed to the extent it does not exceed the carrying amount that would have been determined after considering depreciation / amortisation had no impairment loss been recognised in earlier years.

3. Significant Accounting Policies

3.1. Presentation and disclosure of standalone financial statement

All assets and liabilities have been classified as current and non-current as per Company's normal operating cycle and other criteria set out in the division II of Schedule III of the Companies Act, 2013 for a company whose financial statements are made in compliance with the Companies (India Accounting Standards) Rules, 2015.

Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents, 12 months has been considered by the Company for the purpose of current / non-current classification of assets and liabilities.



3.2. Property, Plant and Equipment and Depreciation

Recognition and measurement

Properties plant and equipment are stated at their cost of acquisition. Cost of an item of property, plant and equipment includes purchase price including non-refundable taxes and duties, borrowing cost directly attributable to the qualifying asset, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and the present value of the expected cost for the dismantling/decommissioning of the asset.

Parts (major components) of an item of property, plant and equipment having different useful lives are accounted as separate items of property, plant and equipment.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company. All other repair and maintenance costs are recognised in statement of profit and loss as incurred.

Capital work-in-progress comprises of cost incurred on property, plant and equipment under construction / acquisition that are not yet ready for their intended use at the Balance Sheet Date.

Depreciation and useful lives

Depreciation on the property, plant and equipment (other than freehold land and capital work in progress) is provided on written own value (WDV) over their useful lives which is in consonance of useful life mentioned in Schedule II to the Companies Act, 2013.

Building on leasehold lands and improvements to building on leasehold land / premises are amortized over the period of lease or useful life whichever is lower.

Depreciation methods, useful lives and residual values are reviewed at each financial year end and adjusted prospectively.

De-recognition

An item of property, plant and equipment and any significant part initially recognised is de-recognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is de-recognised.

3.3. Intangible assets and amortisation

Recognition and measurement

Intangible assets are recognized only if it is probable that the future economic benefits attributable to asset will flow to the Company and the cost of asset can be measured reliably. Intangible assets are stated at cost of acquisition/development less accumulated amortization and accumulated impairment loss if any.

Cost of an intangible asset includes purchase price including non - refundable taxes and duties, borrowing cost directly attributable to the qualifying asset and any directly attributable expenditure on making the asset ready for its intended use.

Intangible assets under development comprises of cost incurred on intangible assets under development that are not yet ready for their intended use as at the Balance Sheet date.

Amortization and useful lives

Computer softwares are amortized over 3-5 years on written down value basis. Intangible Rights are amortized over the period of right to use. Amortization methods and useful lives are reviewed at each financial year end and adjusted prospectively.

In case of assets purchased during the year, amortization on such assets is calculated on pro-rata basis from the date of such addition

3.4. Inventories

Inventories consisting of stock-in-trade are valued at cost or net realisable value, whichever is lower. Cost of inventories also include all other costs incurred in bringing the inventories to their present location and condition.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

The factors that the Company considers in determining the allowance for slow moving, obsolete and other non-saleable inventory includes estimated shelf life, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Company's business and markets. The Company considers all these factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.

3.5. Revenue recognition

Sale of goods

Revenue from sale of goods is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration entitled in exchange for those goods or services.

Generally, control is transferred upon shipment of goods to the customer or when the goods is made available to the customer, provided transfer of title to the customer occurs and the Company has not retained any significant risks of ownership or future obligations with respect to the goods shipped.

Revenue is measured at the amount of consideration which the Company expects to be entitled to in exchange for transferring distinct goods or services to a customer as specified in the contract, net of returns and allowances, trade discounts and volume rebates and excluding amounts collected on behalf of third parties (for example taxes and duties collected on behalf of the government). Consideration is generally due upon satisfaction of performance obligations and the receivable is recognized when it becomes unconditional.

Revenue from sale of goods in the course of ordinary activities is measured at the fair value of the consideration received or receivable and are also netted off for probable saleable and non-saleable return of goods from the customers, estimated on the basis of historical data of such returns.

Income from Services

Revenue from rendering of services is recognised over time where the Company satisfies the performance obligation over time or point in time where the Company satisfies the performance obligation at a point in time.

Advance from customers

Advance from Customers: when a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognised and disclosed as advances from customers.

Interest

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss.



Export Incentive

Export benefits available under prevalent schemes are accrued in the year in which the goods are exported, and no significant uncertainty exist regarding its ultimate collection.

3.6. Foreign currency transaction

Transactions denominated in foreign currencies are recorded at the exchange rates prevailing on the date of the transaction. As at the Balance Sheet date, foreign currency monetary items are translated at closing exchange rate. Exchange difference arising on settlement or translation of foreign currency monetary items are recognised as income or expense in the year in which they arise.

Foreign currency non-monetary items which are carried at historical cost are reported using the exchange rate at the date of transactions.

3.7. Employee benefits

- Short term employee benefits

All employee benefits falling due wholly within twelve months of rendering the service are classified as short term employee benefits and they are recognized as an expense at the undiscounted amount in the Statement of Profit and Loss in the period in which the employee renders the related service.

- Post-employment benefits & other long term benefits

The company has considered valuation of long term employee benefits as per the certificate received from actuarial valuer. For gratuity plan, re-measurements comprising of actuarial gains and losses are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through other comprehensive income in the period in which they occur. Such re-measurements are not reclassified to statement of profit and loss in subsequent periods.

The interest cost on defined benefit obligation is recognised under finance cost.

Actuarial gains or losses arising on account of experience adjustment and the effect of changes in actuarial assumptions for other employee benefit plan [other than gratuity] are recognized immediately in the Statement of Profit and Loss as income or expense.

3.8. Borrowing cost

Borrowing costs (net of interest income on temporary investments) that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of the respective asset till such time the asset is ready for its intended use or sale. A qualifying asset is an asset which necessarily takes a substantial period of time to get ready for its intended use or sale. Ancillary cost of borrowings in respect of loans not disbursed are carried forward and accounted as borrowing cost in the year of disbursement of loan. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest expenses calculated as per effective interest method, exchange difference arising from foreign currency borrowings to the extent they are treated as an adjustment to the borrowing cost and other costs that an entity incurs in connection with the borrowing of funds.

3.9. Leases

The Company evaluates each contract or arrangement, whether it qualifies as lease as defined under Ind AS 116.

Where Company is lessee

The Company enters into an arrangement for lease of office buildings. Such arrangements are generally for a fixed period but may have extension or termination options. The Company assesses, whether the contract is, or contains, a lease, at its inception. A contract is, or contains, a lease if the contract conveys the right to –

- a) control the use of an identified asset,
- b) obtain substantially all the economic benefits from use of the identified asset, and
- c) direct the use of the identified asset

The Company determines the lease term as the non-cancellable period of a lease, together with periods covered by an option to extend the lease, where the Company is reasonably certain to exercise that option.

The Company at the commencement of the lease contract recognizes a Right-of-Use (RoU) asset at cost and corresponding lease liability, except for leases with term of less than twelve months (short term leases) and low-value assets. For these short term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the lease term.

The cost of the right-of-use asset comprises the amount of the initial measurement of the lease liability, any lease payments made at or before the inception date of the lease, plus any initial direct costs, less any lease incentives received. Subsequently, the right-of-use assets are measured at cost less any accumulated depreciation and accumulated impairment losses, if any. The right-of-use assets are depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful life of right-of-use assets are determined on the same basis as those of property, plant and equipment.

The Company applies Ind AS 36 to determine whether an RoU asset is impaired and accounts for any identified impairment loss as described in the impairment of non-financial assets below.

For lease liabilities at the commencement of the lease, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined, if that rate is not readily determined, the lease payments are discounted using the incremental borrowing rate that the Company would have to pay to borrow funds, including the consideration of factors such as the nature of the asset and location, collateral, market terms and conditions, as applicable in a similar economic environment.

After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made.

The Company recognizes the amount of the re-measurement of lease liability as an adjustment to the right-of-use assets. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognizes any remaining amount of the re-measurement in statement of profit and loss.

Lease liability payments are classified as cash used in financing activities in the statement of cash flows.

Where Company is lessor

Leases under which the Company is a lessor, are classified as finance or operating leases. Lease contracts where all the risks and rewards are substantially transferred to the lessee, the lease contracts are classified as finance leases. All other leases are classified as operating leases.

3.10. Taxes on income

Tax expenses for the year comprises of current tax, deferred tax charge or credit and adjustments of taxes for earlier years. In respect of amounts adjusted outside profit or loss (i.e. in other comprehensive income or equity), the corresponding tax effect, if any, is also adjusted outside profit or loss.



Provision for current tax is made as per the provisions of Income Tax Act, 1961.

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognised for all taxable temporary differences, and deferred tax assets are recognised for all deductible temporary differences, carry forward tax losses and allowances to the extent that it is probable that future taxable profits will be available against which those deductible temporary differences, carry forward tax losses and allowances can be utilised.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxation authority.

Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which such deferred tax assets can be utilized. In situations where the Company has unused tax losses and unused tax credits, deferred tax assets are recognised only if it is probable that they can be utilized against future taxable profits. Deferred tax assets are reviewed for the appropriateness of their respective carrying amounts at each Balance Sheet date.

At each reporting date, the Company re-assesses unrecognised deferred tax assets. It recognises previously unrecognised deferred tax assets to the extent that it has become probable that future taxable profit allow deferred tax assets to be recovered.

3.11. Cash and cash equivalents

Cash and cash equivalents include cash in hand, bank balances, deposits with banks (other than on lien) and all short term and highly liquid investments that are readily convertible into known amounts of cash and are subject to an insignificant risk of changes in value.

For the purpose of cash flow statement, cash and cash equivalent as calculated above also includes outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

3.12. Cash flow statement

Cash flows are reported using the indirect method, where by net profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities are segregated.

3.13. Provisions, contingent liabilities, contingent assets

A provision is recognised when the Company has a present obligation (legal or constructive) as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. If the effect of time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risk specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not require an outflow of resources. When there is a possible obligation or a

present obligation in respect of which likelihood of outflow of resources is remote, no provision or disclosure is made.

Provisions, contingent liabilities, contingent assets and commitments are reviewed at each balance sheet date.

3.14. Earnings per share

Basic earnings per share is computed using the net profit for the year attributable to the shareholders' and weighted average number of shares outstanding during the year. The weighted average numbers of shares also includes fixed number of equity shares that are issuable on conversion of compulsorily convertible preference shares, debentures or any other instrument, from the date consideration is receivable (generally the date of their issue) of such instruments.

Diluted earnings per share is computed using the net profit for the year attributable to the shareholder' and weighted average number of equity and potential equity shares outstanding during the year including share options, convertible preference shares and debentures, except where the result would be anti-dilutive. Potential equity shares that are converted during the year are included in the calculation of diluted earnings per share, from the beginning of the year or date of issuance of such potential equity shares, to the date of conversion.

3.15. Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss.

3.15.1. Financial assets

All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets.

Classification of financial assets

Debt instruments that meet the following conditions are subsequently measured at amortised cost (except for debt instruments that are designated as at fair value through profit or loss on initial recognition):

- the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and
- the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All other financial assets are subsequently measured at fair value.



Effective interest method

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the gross carrying amount on initial recognition.

Income is recognised on an effective interest basis for debt instruments other than those financial assets classified as at FVTPL. Interest income is recognised in profit or loss and is included in the “Other income” line item.

Investments in equity instruments at FVTOCI

On initial recognition, the Company can make an irrevocable election (on an instrument-by-instrument basis) to present the subsequent changes in fair value in other comprehensive income pertaining to investments in equity instruments. This election is not permitted if the equity investment is held for trading. These elected investments are initially measured at fair value plus transaction costs. Subsequently, they are measured at fair value with gains and losses arising from changes in fair value recognised in other comprehensive income and accumulated in the ‘Reserve for equity instruments through other comprehensive income’. The cumulative gain or loss is not reclassified to profit or loss on disposal of the investments.

A financial asset is held for trading if:

- It has been acquired principally for the purpose of selling it in the near term; or
- On initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has a recent actual pattern of short-term profit-taking; or
- It is a derivative that is not designated and effective as a hedging instrument or a financial guarantee. Dividends on these investments in equity instruments are recognised in profit or loss when the Company’s right to receive the dividends is established, it is probable that the economic benefits associated with the dividend will flow to the entity, the dividend does not represent a recovery of part of cost of the investment and the amount of dividend can be measured reliably. Dividends recognised in profit or loss are included in the ‘Other income’ line item.

Financial assets at fair value through profit or loss (FVTPL)

Investments in equity instruments are classified as at FVTPL, unless the Company irrevocably elects on initial recognition to present subsequent changes in fair value in other comprehensive income for investments in equity instruments which are not held for trading.

Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any dividend or interest earned on the financial asset and is included in the ‘Other income’ line item. Dividend on financial assets at FVTPL is recognised when the Company’s right to receive the dividends is established, it is probable that the economic benefits associated with the dividend will flow to the entity, the dividend does not represent a recovery of part of cost of the investment and the amount of dividend can be measured reliably.

Impairment of financial assets

The Company recognizes loss allowances using the expected credit loss (ECL) model based on ‘simplified approach’ for the financial assets which are not fair valued through profit or loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all other financial assets, expected credit losses are measured at an amount equal to the twelve month ECL, unless there has been a significant increase in credit risk from initial recognition

in which case those are measured at lifetime ECL. The amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized is recognized as an impairment gain or loss in statement of profit and loss.

De-recognition of financial asset

The Company de-recognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

On de-recognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognised in other comprehensive income and accumulated in equity is recognised in profit or loss if such gain or loss would have otherwise been recognised in profit or loss on disposal of that financial asset.

On de-recognition of a financial asset other than in its entirety (e.g. when the Company retains an option to repurchase part of a transferred asset), the Company allocates the previous carrying amount of the financial asset between the part it continues to recognise under continuing involvement, and the part it no longer recognises on the basis of the relative fair values of those parts on the date of the transfer. The difference between the carrying amount allocated to the part that is no longer recognised and the sum of the consideration received for the part no longer recognised and any cumulative gain or loss allocated to it that had been recognised in other comprehensive income is recognised in profit or loss if such gain or loss would have otherwise been recognised in profit or loss on disposal of that financial asset. A cumulative gain or loss that had been recognised in other comprehensive income is allocated between the part that continues to be recognised and the part that is no longer recognised on the basis of the relative fair values of those parts.

3.15.2. Financial liability and equity instrument

Classification as debt or equity

Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognised at the proceeds received, net of direct issue costs. Repurchase of the Company's own equity instruments is recognised and deducted directly in equity. No gain or loss is recognised in profit or loss on the purchase, sale, issue or cancellation of the Company's own equity instruments.

Financial liabilities

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

However, financial liabilities that arise when a transfer of a financial asset does not qualify for de-recognition or when the continuing involvement approach applies, financial guarantee contracts issued by the Company, and commitments issued by the Company to provide a loan at below-market interest rate are measured in accordance with the specific accounting policies set out below.



Financial liabilities at FVTPL

Financial liabilities are classified as at FVTPL when the financial liability is either contingent consideration recognised by the Company as an acquirer in a business combination to which Ind AS 103 applies or is held for trading or it is designated as at FVTPL.

A financial liability is classified as held for trading if:

- it has been incurred principally for the purpose of repurchasing it in the near term; or
- on initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has a recent actual pattern of short-term profit-taking; or
- it is a derivative that is not designated and effective as a hedging instrument.

A financial liability other than a financial liability held for trading or contingent consideration recognised by the Company as an acquirer in a business combination to which Ind AS 103 applies, may be designated as at FVTPL upon initial recognition if:

- such designation eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise;
- the financial liability forms part of a group of financial assets or financial liabilities or both, which is managed and its performance is evaluated on a fair value basis, in accordance with the Company's documented risk management or investment strategy, and information about the grouping is provided internally on that basis; or
- it forms part of a contract containing one or more embedded derivatives, and Ind AS 109 permits the entire combined contract to be designated as at FVTPL in accordance with Ind AS 109.

Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the 'Other income' line item.

However, for non-held-for-trading financial liabilities that are designated as at FVTPL, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognised in other comprehensive income, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss, in which case these effects of changes in credit risk are recognised in profit or loss. The remaining amount of change in the fair value of liability is always recognised in profit or loss. Changes in fair value attributable to a financial liability's credit risk that are recognised in other comprehensive income are reflected immediately in retained earnings and are not subsequently reclassified to profit or loss.

Gains or losses on financial guarantee contracts and loan commitments issued by the Company that are designated by the Company as at fair value through profit or loss are recognised in profit or loss.

Financial liabilities subsequently measured at amortised cost

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortised cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item. The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability or (where appropriate) a shorter period, to the gross carrying amount on initial recognition.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Reclassification

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The management determines change in the business model as a result of external or internal changes which are significant to the Company's operations. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

De-recognition of financial liabilities

The Company de-recognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or have expired. An exchange between with a lender of debt instruments with substantially different terms is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, a substantial modification of the terms of an existing financial liability (whether or not attributable to the financial difficulty of the debtor) is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of the financial liability de-recognised and the consideration paid and payable is recognised in profit or loss.

Recent accounting pronouncements**New amendments issued but not effective**

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 31, 2023, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2023. The effective date for adoption of this amendment is annual periods beginning on or after April 01, 2023. These amendments are not expected to have a material impact on the Company or future reporting periods and on foreseeable future transactions.

Amendment to Ind AS 1 - Presentation of Financial Statements - This amendment requires the entities to disclose their material accounting policies rather than their significant accounting policies.

Amendment to Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors - This amendment has introduced a definition of 'accounting estimates' and included amendments to Ind AS 8 to help entities distinguish changes in accounting policies from changes in accounting estimates.

Amendment to Ind AS 12 - Income Taxes - This amendment has narrowed the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offsetting temporary differences.



4 - Property, Plant and Equipment

(₹ in Lakhs)

Particulars	Building & Premises	Office equipment	Furniture & fixtures	Computer Equipments	Vehicles	Total
Gross Carrying Value						
Balance as at March 31, 2021	72.50	12.54	50.32	6.60	5.16	147.13
Additions	-	1.93	-	0.82	23.67	26.42
Disposals	-	-	-	-	-	-
Balance as at March 31, 2022	72.50	14.48	50.32	7.43	28.83	173.56
Additions	-	3.21	3.22	3.87	-	10.30
Disposals	-	-	-	-	-	-
Balance as at March 31, 2023	72.50	17.68	53.54	11.30	28.83	183.86
Accumulated Depreciation						
Balance as at March 31, 2021	15.91	10.35	38.79	5.48	4.62	75.16
Depreciation expense	2.74	1.38	2.99	1.00	4.50	12.60
Disposals	-	-	-	-	-	-
Balance as at March 31, 2022	18.65	11.73	41.78	6.48	9.12	87.76
Depreciation expense	2.60	2.13	2.75	1.94	6.42	15.84
Disposals	-	-	-	-	-	-
Balance as at March 31, 2023	21.25	13.86	44.53	8.42	15.54	103.60
Carrying amount						
Balance as at March 31, 2022	53.85	2.75	8.54	0.95	19.71	85.80
Balance as at March 31, 2023	51.25	3.83	9.01	2.88	13.29	80.26

Note :

1. The title deeds of all the immovable properties (other than properties where the Company is a lessee and the lease agreements are duly executive in favour of the lessee) are held in the name of the Company.
2. The Company has not carried out any revaluation of its Property, Plant and Equipment during the year, since the Company has adopted cost model as its accounting policy to an entire class of Property, Plant and Equipment in accordance with Ind AS 16.

5 - Right of Use Assets

Particulars	Leasehold Premises	Total
Gross carrying value:		
Balance as at March 31, 2021	64.13	64.13
Additions	-	-
Disposals	-	-
Balance as at March 31, 2022	64.13	64.13
Additions	123.31	123.31
Disposals / Derecognized during the year	(64.13)	(64.13)
Balance as at March 31, 2023	123.31	123.31
Accumulated Depreciation		
Balance as at March 31, 2021	39.05	39.05
Depreciation expense	20.53	20.53
Disposals	-	-
Balance as at March 31, 2022	59.58	59.58
Depreciation expense	23.77	23.77

Disposals	(59.58)	(59.58)
Balance as at March 31, 2023	23.77	23.77
Net book value as at March 31, 2022	4.56	4.56
Net book value as at March 31, 2023	99.53	99.53

6 - Intangible assets

	(₹ in Lakhs)		
Particulars	Computer Software	Intangible Rights	Total
<u>Cost or Deemed Cost</u>			
Balance as at March 31, 2021	2.49	74.80	77.29
Additions	-	15.35	15.35
Balance as at March 31, 2022	2.49	90.15	92.64
Additions	1.45	-	1.45
Derecognised during the year	-	16.68	16.68
Balance as at March 31, 2023	3.94	73.47	77.41
<u>Amortisation</u>			
Balance as at March 31, 2021	2.49	49.98	52.47
Amortisation expense	-	12.50	12.50
Balance as at March 31, 2022	2.49	62.48	64.96
Amortisation expense	0.40	10.32	10.73
Derecognised during the year	-	16.68	16.68
Balance as at March 31, 2023	2.89	56.12	59.01
<u>Carrying Amount</u>			
Balance as at March 31, 2022	-	27.68	27.68
Balance as at March 31, 2023	1.05	17.35	18.40

Note :

The Company has not revalued its intangible asset, since the Company has adopted cost model as its accounting policy to an entire class of Intangible Asset in accordance with Ind AS 38.

	(₹ in Lakhs)
Intangible assets under development	Total
Balance as at 31st March 2022	49.24
Balance as at March 31, 2023	67.21

The table below provides details regarding the intangible work in progress ageing schedule as at March 31, 2023

	(₹ in Lakhs)				
Particulars	Less than 1 year	1-2 years	2-3 years	More the 3 years	Total
Intangible assets under development	17.97	49.24	-	-	67.21
Intangibles temporary Suspended	-	-	-	-	-
Total	17.97	49.24	-	-	67.21

The table below provides details regarding the intangible work in progress ageing schedule as at March 31, 2022



(₹ in Lakhs)

Particulars	Less than 1 year	1-2 years	2-3 years	More the 3 years	Total
Intangible assets under development	49.24	-	-	-	49.24
Intangibles temporary Suspended	-	-	-	-	-
Total	49.24	-	-	-	49.24

There is no Intangibles under work in progress, whose completion is either overdue or has exceeded its cost compared to its original cost as on March 31, 2023 and March 31, 2022.

7 - Investments

(₹ in Lakhs)

Sr no	Particulars	As at March 31, 2023		As at March 31, 2022	
		Nos.	Amount	Nos.	Amount
	<u>Non- current</u>				
	<u>Unquoted (at Cost)</u>				
1.	Equity shares of Janata Sahakari Bank Ltd of Rs. 100 each	43,130	43.13	43,130	43.13
2.	Equity shares of City Cooperative Bank Ltd of Rs. 10 each	100	0.01	100	0.01
3.	Equity shares of Shamrao Vithal Co-operative Bank Ltd of Rs. 10 each		0.01		0.01
	Sub-total		43.15		43.15
	Aggregate carrying value of unquoted investments (Net of provision) - Non current		43.15		43.15

Note :

1. The company has obtained equity shares of Janata Sahakari Bank Limited in pursuant to working capital loan obtained from the same bank, hence the fair value of such share certificate will be equal to face value.

8 - Other Financial Assets

(₹ in Lakhs)

		As at March 31, 2023	As at March 31, 2022
8A	<u>Non-current</u>		
	<u>Unsecured, Considered Good unless otherwise stated)</u>		
	Security Deposits	99.05	98.55
	Interest receivable on Margin money deposit	8.38	58.25
	Bank deposits with maturity of more than twelve (12) months	120.62	65.00
	Non-current total	228.06	221.80
8B	<u>Current</u>		
	<u>Unsecured, Considered Good unless otherwise stated)</u>		
	Advance recoverable in cash or kind	1,143.89	1,186.04
	Current total	1,143.89	1,186.04
	Total	1,371.95	1,407.85

For the financial assets that are measured at amortised cost, the fair values are not materially different from their carrying amounts, since they are either of short term nature or interest receivable is close to current market rates. (Refer Note 29B)

In case of Deposits where the period is not defined, there is no appropriate representative interest rate and period which can be applied to amortise these deposits. Hence, these deposits are valued at transaction value and are not amortised.

9 - Income Taxes

A Income Tax Expense in the Statement of Profit and Loss comprises : (₹ in Lakhs)

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Current Income Taxes	215.74	145.48
Deferred Income Taxes	0.43	(1.82)
Income Tax Expense (net)	216.17	143.66

B A reconciliation of the income tax provision to the amount computed by applying the statutory income tax rate to the profit before income taxes is as below:

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Profit before income tax	884.62	572.84
Applicable income tax rate	25.16%	25.16%
Computed expected tax expense	222.57	144.13
Disallowance under Income tax	(6.40)	(0.47)
Income tax expense charged to the Statement of Profit and Loss	216.17	143.66

C Components of deferred income tax assets and liabilities arising on account of temporary differences are:

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Deferred Income Tax Asset		
Timing difference on tangible and intangible assets depreciation and amortization	7.01	10.32
Timing difference on gratuity expense	5.37	5.64
Timing difference on leases	1.95	0.10
Timing difference on non payment of statutory dues	0.01	0.01
Total Deferred Income Tax Asset (net)	14.34	16.07

D Reconciliation of Deferred Tax movement during the year

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Opening Differed Tax Assets	16.07	14.81
Deferred Tax Assets recognised through profit and loss on timing difference	(0.43)	1.82
Deferred Tax Assets recognised through OCI on employee benefits	(1.31)	(0.55)
Total Deferred Income Tax Asset (net)	14.33	16.08



10 - Other Assets

(₹ in Lakhs)

	As at March 31, 2023	As at March 31, 2022
10A Non-current		
VAT receivable	44.36	44.80
Other Receivables	26.99	26.17
Prepaid expenses	0.38	0.29
Non-current total	71.73	71.26
10B Current		
Export benefit receivables	37.22	31.80
Advances to Suppliers	264.48	333.50
Prepaid expenses	5.30	6.92
Balances with Customs, Port Trust, Central Excise etc.	51.73	35.62
Current total	358.73	407.84
Total	430.46	479.10

11 - Inventories

(₹ in Lakhs)

	As at March 31, 2023	As at March 31, 2022
Inventories (lower of cost and net realisable value)		
Stock-in-trade (Refer Note 35)	305.01	62.90
Total	305.01	62.90

12 - Trade receivables

(₹ in Lakhs)

	As at 31st March 2023	As at 31st March 2022
Secured, Considered good		
Unsecured, considered good	5,361.01	5,850.54
More than six months	3,650.90	3,472.52
Less than six months	1,710.11	2,378.03
Doubtful		
Allowance for doubtful debts (expected credit loss allowance)	-	-
	5,361.01	5,850.54

Note

1 The Company's exposure to credit, liquidity and market risks, and loss allowances related to Trade Receivables is disclosed in Note 29.

Provision Matrix

The Company has robust policy of provisioning the debtors. The Overdue debtors above 1 year is critically reviewed and necessary provision between 50% to 100% is done on case to case basis post evaluation.

Ageing for trade receivable from the due date of payment for each of the category is as at March 31, 2023 as follows :

(₹ in Lakhs)							
Particulars	Not due	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years	Total
Unsecured, considered good							
Undisputed		1,710.11	325.53	330.16	376.63	2,618.58	5,361.01
Disputed		-	-	-	-	-	-
Considered Doubtful							
Undisputed		-	-	-	-	-	-
Disputed		-	-	-	-	-	-
Total		1,710.11	325.53	330.16	376.63	2,618.58	5,361.01

Ageing for trade receivable from the due date of payment for each of the category is as at March 31, 2022 as follows :

Particulars	Not due	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years	Total
Unsecured, considered good							
Undisputed		2,378.03	424.63	536.47	475.90	2,035.52	5,850.54
Disputed		-	-	-	-	-	-
Considered Doubtful							
Undisputed		-	-	-	-	-	-
Disputed		-	-	-	-	-	-
Total		2,378.03	424.63	536.47	475.90	2,035.52	5,850.54

13 - Cash and cash equivalents

(₹ in Lakhs)		
Particulars	As at March 31, 2023	As at March 31, 2022
Cash on hand		
- In Indian Currency	5.91	22.66
Balances with Banks		
- In current accounts	47.01	93.56
	52.92	116.23

14 - Bank balances other than Cash and cash equivalents

Particulars	As at March 31, 2023	As at March 31, 2022
Balance with bank earmarked as margin money	45.56	19.30
	45.56	19.30

15 - Equity Share capital

(₹ in Lakhs)			
	As at March 31, 2023		As at March 31, 2022
	Numbers	Amount	Numbers Amount
Authorised Share Capital			
Equity shares of Rs.10/- each	22,000,000	2,200.00	22,000,000 2,200.00



Non-cumulative Redeemable Preference Shares of Re. 1 each	-	-
	2,200.00	2,200.00
Issued, subscribed and fully paid up Equity share capital		
Equity shares of Rs.10/- each	10,546,213	1,054.62
	10,546,213	1,055

- (a) Reconciliation of the number of equity shares outstanding at the beginning and at the end of the period:

	March 31, 2023		March 31, 2022	
	No of shares	Amount	No of shares	Amount
Equity shares:				
At the beginning of the period	10,546,213	1,054.62	10,546,213	1,054.62
Add: Issued during the year	-	-	-	-
At the end of the period	10,546,213	1,054.62	10,546,213	1,054.62

Note

During the financial year 2017-18 the company has converted unsecured loans by issue of share capital. The company has issued 16,15,385 shares at a premium of Rs. 3 per share having a face value of Rs. 10 per share

The company has also issued 19,76,000 shares by way of Initial Public Offer at a premium of Rs. 62 per share in financial year 2017-18.

During the financial year 2019-20 the company had issued 39,54,828 bonus shares having face value of Rs. 10 per share amounting to Rs. 3,95,48,280 by utilising the Securities Premium Reserve.

- (b) **Rights and terms attached to equity shares**

The Company has only one class of equity shares each having par value of Rs.10 per share. The holder of equity shares is entitled to one vote per share. All these shares have the same rights and preferences with respect to payment of dividend, repayment of capital and voting rights. The Company declares and pays dividends on shares in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

- (c) **Share application money pending allotment (Share Warrant)**

	(₹ in Lakhs)	
	As at March 31, 2023	As at March 31, 2022
At the beginning of the year	-	-
During the year	756.02	-
Allotted during the year	-	-
Outstanding at the end of the year	756.02	-

(d) Details of shareholders holding more than 5% shares of the company

Name of the Shareholders	As at March 31, 2023		As at March 31, 2022	
	No of shares	% holding in the class	No of shares	% holding in the class
<u>Equity shares of Rs.10 each fully paid</u>				
1) Mr. Atul Arvind Vasani	2,262,023	21.45%	2,262,023	21.45%
2) Mr. Sapan Anil Shah	766,079	7.26%	348,356	3.30%
3) Ms. Nupur Anil Shah	626,422	5.94%	605,000	5.74%

(e) Details of share held by promoters of the company

Name of the Promoters	As at March 31, 2023		As at March 31, 2022		% Changes during the Year
	No of shares	% holding in the class	No of shares	% holding in the class	
<u>Equity shares of Rs.10 each fully paid</u>					
1) Mr. Atul Arvind Vasani	2,262,023	21.45%	2,262,023	21.45%	0.00%
2) Mrs. Jagruti Atul Vasani	479,992	4.55%	479,992	4.55%	0.00%

As per records of the Company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

16 - Financial liabilities

		(₹ in Lakhs)	
		As at March 31, 2023	As at March 31, 2022
16A Non- Current Borrowings			
Secured:			
Term Loan			
- from Banks		546.09	275.92
Secured			
- from Non Banking Financial Company		86.03	104.75
Unsecured			
- from Non Banking Financial Company		-	26.18
Total Non-Current Borrowings		632.12	406.85
Less : Current portion of long term borrowings disclosed under the head other current liabilities		109.44	96.23
Non- Current Borrowings (as per balance sheet)		522.68	310.62
16B Current Borrowings			
Secured			
Cash credit from banks		668.05	1,122.36
Unsecured			
Loans from Related Party (Refer Note 32)		66.17	547.00
Current portion of long term borrowings		109.44	96.23
Current Borrowings (as per balance sheet)		843.66	1,765.59



Note:-

Non-Current Borrowing

1. Working Capital Term Loan from Janata Sahakari Bank Ltd of Rs 3,00,00,000/- is secured by the collateral security by equitable mortgage of assets owned by Directors and their family members and by lien of Fixed Deposit placed by the company with the bank repayable in 84 monthly installments commencing from January 2019, and carries an interest rate of 11.00%
2. Working Capital Term Loan from Janata Sahakari Bank Ltd of Rs. 3,50,00,000/- is secured by the collateral security by equitable mortgage of assets owned by Directors and their family members and by lien of Fixed Deposit placed by the company with the bank repayable in 60 monthly installments commencing from March 2023, and carries an interest rate of 11.00%
3. Term Loan taken from L&T Housing Finance Ltd (NBFC) of Rs. 50,97,145/- (29.21% of Rs 1,74,50,000/-), 64,00,000/- & 25,99,900/- is secured by mortgage of immovable property and is repayable in 120 monthly installments commencing from March 2015, April 2017, and October 2020 and carries an effective interest rate of 9.60%, 10.10% & 9.60%.
4. The unsecured loan taken from directors is interest free. The loan is re-payable on demand.
- 5.

Bank name	Rate of interest p.a	No. of instalments pending	Installment Amount	Commencement from
Janata Sahakari Bank Ltd, Pune	11.00%	60	775,000	Mar-23
Janata Sahakari Bank Ltd, Pune	11.00%	31	516,000	Mar-18
L & T Housing Finance	9.60%	36	252,886	Mar-15
L & T Housing Finance	10.10%	61	89,982	Apr-17
L & T Housing Finance	9.60%	24	88,862	Oct-20

6. There is no default in repayment of Loans.

Current Borrowing

1. Cash Credit facility from Janata Sahakari Bank Ltd, Pune secured against primary security of hypothecation of stock & book debts & equitable mortgage of properties owned by directors & their relatives, fixed deposits liened to the facilities & personal guarantee of directors & owners of the properties.

Note 17: Lease Liabilities

(a) Break up of current and non-current lease liabilities as at 31st March, 2023 (₹ in Lakhs)

Particulars	As at March 31, 2023	As at March 31, 2022
Non-current lease liabilities	88.22	3.75
Current lease liabilities	19.06	1.17
Total	107.29	4.92

(b) The movement in lease liabilities during the year ended 31st March, 2023 is as follows:

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Balance at the beginning of the year	4.92	27.56
Additions	123.31	-
Finance cost accrued during the year	11.97	1.84
Disposed off during the Year	(4.92)	-
Payment of lease liabilities	(27.99)	(24.48)
Balance at the end	107.29	4.92

18 - Provisions

(₹ in Lakhs)		
	As at March 31, 2023	As at March 31, 2022
18A Non-current		
Provision for employee benefits Gratuity (Refer Note 25)	18.92	18.91
Non-current total	18.92	18.91
18B Current		
Provision for employee benefits Gratuity (Refer Note 25)	2.41	3.49
Current total	2.41	3.49
Total	21.32	22.40

19 - Trade payables

(₹ in Lakhs)		
	As at 31st March 2023	As at 31st March 2023
Trade payables		
Due to Micro, Small and Medium Enterprises*	61.52	161.44
Other than Micro, Small and Medium Enterprises	1,738.15	2,676.63
	1,799.67	2,838.07

* The information as required to be disclosed under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) has been determined to the extent such parties have been identified on the basis of information available with the Company.

(₹ in Lakhs)		
	As at 31st March 2023	As at 31st March 2023
Principal amount and interest due:		
Principal amount	61.52	161.44
Interest paid by Buyer in terms of section 16 of MSMED Act	-	-
Amount paid beyond the appointed day	-	-
Interest due and payable to supplier, for payment already made under MSMED Act	-	-
Amount of Interest accrued and remaining unpaid at the end of accounting year	-	-
Amount of further interest remaining due and payable even in succeeding years	-	-

Ageing for trade payables from due date of payment for each of the category as at March 31, 2023 as follows :

(₹ in Lakhs)						
Particulars	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Due to MSME		29.39	17.35	8.86	5.91	61.52
Undisputed Due to Party's Other than MSME		952.30	72.32	18.36	695.17	1,738.15
Disputed Due to MSME		-	-	-	-	-
Disputed Due to Party's Other than MSME		-	-	-	-	-
(Includes creditors for goods and expenses)						
Total		981.70	89.67	27.22	701.08	1,799.67



Ageing for trade payables from due date of payment for each of the category is as at March 31, 2022 as follows :

(₹ in Lakhs)						
Particulars	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Due to MSME		123.05	19.63	5.77	12.99	161.44
Undisputed Due to Party's Other than MSME		1,796.70	29.30	407.84	442.79	2,676.63
Disputed Due to MSME		-	-	-	-	-
Disputed Due to Party's Other than MSME		-	-	-	-	-
(Includes creditors for goods and expenses)						
Total		1,919.75	48.93	413.61	455.78	2,838.07

20 - Other financial liabilities

(₹ in Lakhs)		
	As at March 31, 2023	As at March 31, 2022
Current		
Interest accrued but not due on borrowings	0.59	1.92
Employee payables (Refer note 32)	31.60	36.44
Accrual for expenses (Refer note 32)	1.78	18.03
	33.97	56.39

For the financial liabilities that are measured at amortised cost, the fair values are not materially different from their carrying amounts, since they are of short term nature. (Refer Note 29B)

21 - Other liabilities

(₹ in Lakhs)		
	As at March 31, 2023	As at March 31, 2022
Current		
Advances from customers	175.61	250.24
Statutory Dues	137.79	151.57
	313.40	401.81

22 - Revenue from Operations

(₹ in Lakhs)		
	Year ended March 31, 2023	Year ended March 31, 2022
Sale of Products		
(i) Domestic	4,536.85	5,594.05
(ii) Exports	1,845.60	1,559.63
Other operating revenue		
(i) Commission Income	557.72	410.04
(ii) Export Incentive	26.11	18.36
	6,966.28	7,582.08

23 - Other income

(₹ in Lakhs)		
	Year ended March 31, 2023	Year ended March 31, 2022
Interest income earned on financial assets not designated as at FVTPL		

Bank deposits	8.06	8.59
Other financial assets	117.44	121.17
Dividend income on equity shares at FVTPL	0.00	0.00
Excess provision / mis write back	9.78	4.73
Foreign currency transactions and translation gain (net)	54.14	44.32
Miscellaneous Income	33.45	0.00
	222.87	178.81

24 - Changes in inventories of finished goods, stock-in-trade and work-in-progress

	Year ended March 31, 2023	Year ended March 31, 2022
Opening inventories		
Stock-in-trade	62.90	58.82
	62.90	58.82
Closing inventories		
Stock-in-trade	305.01	62.90
	305.01	62.90
Total	(242.11)	(4.07)

25 - Employee benefits expense

(₹ in Lakhs)

	Year ended March 31, 2023	Year ended March 31, 2022
Salaries, wages and bonus	118.12	120.67
Directors Remuneration (Refer note)	78.00	73.84
Gratuity Expenses	4.12	4.35
Contribution to provident funds and other funds	4.06	4.77
Employees' welfare expenses	3.79	6.29
	208.08	209.92

Employee benefit plans
25A Gratuity and other post-employment benefit plans

The Company operates a defined gratuity plan for its employees. Under the gratuity plan, every employee who has completed five years or more of service gets a gratuity on death or resignation or retirement at 15 days salary (last drawn salary) for each completed year of service. The scheme is unfunded.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet for the respective plans.

Statement of profit and loss

Net employee benefit expenses recognised in the employee cost

Actuarial Risk	It is the risk that benefits will cost more than expected. This can arise due to one of the following reasons: Adverse Salary Growth Experience: Salary hikes that are higher than the assumed salary escalation will result into an increase in Obligation at a rate that is higher than expected.
-----------------------	---



	<p>Variability in mortality rates: If actual mortality rates are higher than assumed mortality rate assumption than the Gratuity Benefits will be paid earlier than expected. Since there is no condition of vesting on the death benefit, the acceleration of cashflow will lead to an actuarial loss or gain depending on the relative values of the assumed salary growth and discount rate.</p> <p>Variability in withdrawal rates: If actual withdrawal rates are higher than assumed withdrawal rate assumption than the Gratuity Benefits will be paid earlier than expected. The impact of this will depend on whether the benefits are vested as at the resignation date.</p>
Investment risk	For funded plans that rely on insurers for managing the assets, the value of assets certified by the insurer may not be the fair value of instruments backing the liability. In such cases, the present value of the assets is independent of the future discount rate. This can result in wide fluctuations in the net liability or the funded status if there are significant changes in the discount rate during the inter-valuation period.
Liquidity Risk	Employees with high salaries and long durations or those higher in hierarchy, accumulate significant level of benefits. If some of such employees resign/retire from the company there can be strain on the cashflows.
Legislative Risk	Legislative risk is the risk of increase in the plan liabilities or reduction in the plan assets due to change in the legislation/regulation. The government may amend the Payment of Gratuity Act thus requiring the companies to pay higher benefits to the employees. This will directly affect the present value of the Defined Benefit Obligation and the same will have to be recognized immediately in the year when any such amendment is effective.

The principal assumptions used for the purposes of the actuarial valuations were as follows.

Particulars	Valuation as at		Valuation as at	
	Year ended March 31, 2023		Year ended March 31, 2022	
Discount rate(s)	7.50%		7.25%	
Expected rate(s) of salary increase	7.00%		7.00%	
Mortality rates	Age(Years)	Rates (p.a.)	Age(Years)	Rates (p.a.)
	20	0.09%	20	0.09%
	30	0.10%	30	0.10%
	40	0.17%	40	0.17%
	50	0.44%	50	0.44%
	60	1.12%	60	1.12%

Amounts recognised in the Statement of profit and loss in respect of these defined benefit plans are as follows.

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Service cost:		
Current service cost	2.62	3.03
Past service cost and gain from settlements	-	-
Interest on net defined benefit asset	1.50	1.32
Components of defined benefit costs recognised in profit or loss	4.12	4.35
Actuarial (gains) / losses arising from changes in financial assumptions	(0.59)	(1.15)
Actuarial (gains) / losses arising from changes in demographic assumptions	-	-
Actuarial (gains) / losses arising from experience adjustments	(4.61)	(1.05)
Components of defined benefit costs recognised in other comprehensive income	(5.20)	(2.20)

The current service cost and the net interest expense for the year are included in the 'Employee benefits expense' line item in the statement of profit and loss.

The re-measurement of the net defined benefit liability is included in other comprehensive income. Movements in the present value of the defined benefit obligation are as follows.

A) Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Opening defined benefit obligation	22.40	20.25
Current service cost	2.62	3.03
Interest cost	1.50	1.32
Re-measurement (gains)/losses:		
Actuarial gains and losses arising from changes in financial assumptions	(0.59)	(1.15)
Actuarial gains and losses arising from changes in demographic assumptions	-	-
Actuarial gains and losses arising from experience adjustments	(4.61)	(1.05)
Past service cost, including losses/(gains) on curtailments	-	-
Benefits paid	-	-
Closing defined benefit obligation	21.32	22.40

25B Sensitivity Analysis:

Gratuity is a lump sum plan and the cost of providing these benefits is typically less sensitive to small changes in demographic assumptions. The key actuarial assumptions to which the benefit obligation results are particularly sensitive to are discount rate and future salary escalation rate. The following table summarizes the impact in percentage terms on the reported defined benefit obligation (DBO) at the end of the reporting period arising on account of an increase or decrease in the reported assumption by 50 basis points.

B) Particulars	Year Ended 31st March, 2023		Year Ended 31st March, 2022	
	Discount Rate	Salary Escalation Rate	Discount Rate	Salary Escalation Rate
Impact of increase in 50 bps on DBO	-5.19%	4.38%	-5.22%	4.64%
Impact of decrease in 50 bps on DBO	5.67%	-4.21%	5.72%	-4.40%

These sensitivities have been calculated to show the movement in defined benefit obligation in isolation and assuming there are no other changes in market conditions at the accounting date. There have been no changes from the previous periods in the methods and assumptions used in preparing the sensitivity analysis.

The average duration of the benefit obligation at 31st March 2023 is 13.17 years, (as at 31st March 2022: 12.86 years).

Projected Plan Cash Flow:

The table below shows the expected cash flow profile of the benefits to be paid to the current membership of the plan based on past service of the employees as at the valuation date:



	(₹ in Lakhs)	
Maturity Profile	2022-23	2021-22
Expected benefits for year 1	2.41	3.49
Expected benefits for year 2	2.59	0.81
Expected benefits for year 3	0.75	2.59
Expected benefits for year 4	0.78	0.74
Expected benefits for year 5	0.79	0.78
Expected benefits for year 6 and above	5.11	4.85

26 - Finance costs	(₹ in Lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Interest expenses on short term borrowings, bank overdraft and others	188.89	244.04
Interest on unwinding of leases liability	11.97	1.84
Other borrowing costs		
	200.85	245.88

27 - Depreciation and amortisation expense	(₹ in Lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Depreciation of Property, Plant and Equipment pertaining to continuing operations (Refer Note 4)	16.34	12.60
Depreciation on Right of use asset (Refer Note 5)	23.77	20.53
Amortisation of Intangible assets (Refer Note 6)	10.32	12.50
	50.44	45.63

28 - Other expenses	(₹ in Lakhs)	
	Year ended March 31, 2023	Year ended March 31, 2022
Repairs and Maintenance	2.24	1.63
Brokerage and Commission	15.24	112.39
Rent (Refer note 32)	-	2.78
Insurance	1.26	1.17
Rates and Taxes	2.55	1.45
Advertisement and Sales Promotion Expenses	52.92	8.60
Travelling and Conveyance	29.48	11.92
Carriage and Freight	201.02	146.33
Director Sitting Fees	0.26	0.89
Printing & Stationery	6.18	3.29
Office expenses	4.89	2.36
Interest and penalty	24.78	3.00
Postage, Telephone and Electricity	12.79	10.00
Legal, Professional and Consultancy Charges (Refer note 28A)	23.70	30.64
Donations	0.03	0.11
Miscellaneous Expenses	0.04	0.02
	377.40	336.57

		(₹ in Lakhs)	
28A	Legal and professional expenses include:	Year ended March 31, 2023	Year ended March 31, 2022
	Auditors' remuneration and expenses		
	Statutory Auditor's Remuneration	0.75	0.75
	Limited Review of Quarterly results	0.50	0.50
	Tax Auditors Fees		
	Taxation matters	0.50	0.50
	Others		
	Fees for other audit related services	0.25	-

28 - Expenditure towards corporate social responsibility (CSR) activities

(a) Gross Amount required to be spent by the Company during the year: Rs. 4.78 Lakhs

(b) Amount spent in Cash during the year on: (₹ in Lakhs)

Particulars	Yet to be Paid	Total
(i) Construction / Acquisition of any Asset	-	-
	-	-
(ii) On purposes other than above	4.78	4.78
	-	-

29 - Risk management

29A Capital Risk

For the purpose of the Company's capital management, capital includes issued equity capital and all other equity reserves attributable to the equity holders of the Company. The Company strives to safeguard its ability to continue as a going concern so that they can maximise returns for the shareholders and benefits for other stake holders. The aim is to maintain an optimal capital structure and minimise cost of capital.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may return capital to shareholders, issue new shares or adjust the dividend payment to shareholders (if permitted).

29B Financial Instruments

The significant accounting policies, including the criteria for recognition, the basis of measurement and the basis on which income & expenses are recognised, in respect of each class of financial asset, financial liability and equity instrument are as disclosed in Note no. 3 to the financial statements.

		(₹ in Lakhs)	
Particulars	As at March 31, 2023	As at March 31, 2022	
<u>Financial assets</u>			
<u>Measured at Fair value through OCI</u>			
Investments	43.15	43.15	
<u>Measured at amortised cost</u>			
Cash and bank balances	52.92	116.23	
Trade receivable	5,361.01	5,850.54	
Security Deposits	99.05	98.55	



Margin Money	45.56	19.30
Interest receivable on Margin Money deposit	8.38	58.25
Fixed Deposit with bank	120.62	65.00
Advance Recoverable in cash or kind	1,143.89	1,186.04
<u>Financial liabilities</u>		
<u>Measured at amortised cost</u>		
<u>Borrowings</u>		
Long Term Borrowings	522.68	310.62
Short Term Borrowings	668.05	1,122.36
Directors' loan	66.17	547.00
<u>Lease Liabilities</u>	107.29	4.92
<u>Measured at amortised cost</u>		
Trade payable	1,799.67	2,838.07
Current Maturities of Long Term Borrowings	109.44	96.23
Employee Benefits payable	31.60	36.44
Accrual for expenses	1.78	18.03
Interest accrued but not due on borrowings	0.59	1.92

The management considers that the carrying amount of financial assets & financial liabilities recognised in the financial statement approximate their fair values.

29C Financial Risk management objectives and policies

The Company's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Company's primary focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its financial performance.

The Company's financial liabilities comprise of borrowings, trade payable and other liabilities to manage its operation and financial assets includes trade receivables and other receivables etc. that arise from its operation.

The Company has constituted a Risk Management Committee consisting of majority of directors and senior managerial personnel. The Company has a robust Business Risk Management framework to identify, evaluate business risks and opportunities. This framework seeks to create transparency, minimize adverse impact on the business objectives and enhance the Company's competitive advantage. The business risk framework defines the risk management approach across the enterprise at various levels including documentation and reporting. The framework has different risk models which help in identifying risks trend, exposure and potential impact analysis at a Company level as also separately for business segments.

The Company has instituted a self governed Risk Management framework based on identification of potential risk areas, evaluation of risk intensity, and clearcut risk mitigation policies, plans and procedures both at the enterprise and operating levels. The framework seeks to facilitate a common organisational understanding of the exposure to various risks and uncertainties at an early stage, followed by timely and effective mitigation. The Audit Committee of the Board reviews the risk management framework at periodic intervals. Our risk management procedures ensure that the management controls various business related risks through means of a properly defined framework.

29D Market Risk

The Company operates internationally and a major portion of the business is transacted in several currencies and consequently the Company is exposed to foreign exchange risk to the extent that there is mismatch between the currencies in which its sales and services and purchases from overseas suppliers in various foreign currencies. Market Risk is the risk that changes in market prices such as foreign exchange rates will effect groups income or value of its holding financial assets/ instruments.

The Company also holds derivative financial instruments such as foreign exchange forward contracts to mitigate the risk of changes in exchange rates on foreign currency exposures. The exchange rate between the Rupee and foreign currencies has changed substantially in recent years and may fluctuate substantially in the future. Consequently, the results of the Company's operations are favourably affected as the Rupee appreciates/ depreciates against US dollar (USD)

The carrying amounts of the Company's foreign currency denominated monetary assets and liabilities at the end of the reporting period which are hedged are as follows.

Particulars	(\$ in Lakhs)			
	Assets		Liabilities	
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2023	As at March 31, 2022
Trade receivables	12.50	3.70	-	-

- (i) This is mainly attributable to the exposure outstanding on foreign currency receivables in the Company at the end of the reporting period.
- (ii) The Company hedges its net exposure in foreign currencies and as such the profit or loss of the company is not subject to foreign exchange fluctuation.

The unhedged foreign currency exposures of the company are as follows :

Particulars	(\$ in Lakhs)			
	Assets		Liabilities	
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2023	As at March 31, 2022
Trade receivables	2.12	9.16	-	-

29E Credit risk

Credit risk refers to the risk of default on its obligation by the customer / counter party resulting in a financial loss. The maximum exposure to the credit risk at the reporting date is carrying value of respective financial assets.

Trade receivables and unbilled revenue are typically unsecured and are derived from revenue earned from customers. Credit risk has always been managed by each business segment through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants credit terms in the normal course of business. On account of adoption of Ind AS 109, the Company uses expected credit loss model to assess the impairment loss or gain. The group uses a provision matrix to compute the expected credit loss allowance for trade receivables and unbilled revenues. The provision matrix takes into account available external and internal credit risk factors such as default risk of industry, credit default swap quotes, credit ratings from international credit rating agencies and historical experience for customers.



Credit risk on cash and cash equivalents is limited as we generally invest in deposits with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies. Investments primarily include investment in shares of co-operative banks.

29F Liquidity Risk

The Company's principle sources of liquidity are cash and cash equivalents, current investments and the cash flow that is generated from operations. The Company believes that the working capital is sufficient to meet its current requirements. Accordingly, no liquidity risk is perceived. The Company closely monitors its liquidity position and maintains adequate source of funding.

The table below provides details regarding the contractual maturities of significant financial liabilities as of 31st March, 2023:

(₹ in Lakhs)				
Particulars	As at March 31, 2023	Less than 1 year	1-5 years	Above 5 years
Borrowings	632.12	109.44	522.68	-
Current Borrowings	668.05	668.05	-	-
Lease Liabilities	107.29		107.29	-
Trade Payables	1,799.67	1,799.67	-	-
Other Financial Liabilities	33.97	33.97	-	-

The table below provides details regarding the contractual maturities of significant financial liabilities as of 31st March, 2022:

(₹ in Lakhs)				
Particulars	As at March 31, 2023	Less than 1 year	1-5 years	Above 5 years
Borrowings	406.85	96.23	310.62	-
Current Borrowings	1,122.36	1,122.36	-	-
Lease Liabilities	4.92	4.92	-	-
Trade Payables	2,838.07	2,838.07	-	-
Other Financial Liabilities	56.39	56.39	-	-

30 - Segment Information

The Company is primarily engaged in only one type of business i.e. marketing of pharmaceutical products including active pharmaceutical ingredients and there are no separate reportable segments.

31 - Earnings per share

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Basic earnings per share		
From continuing operations attributable to the owners of the company	6.26	3.82
Total basic earnings per share attributable to the owners of the company	6.26	3.82
Diluted earnings per share		
From continuing operations attributable to the owners of the company	5.91	3.82
Total diluted earnings per share attributable to the owners of the company	5.91	3.82

Basic / Diluted earnings per share

The earnings and weighted average number of equity share used in the calculations of basic earnings per share are as follows:

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Profit for the year attributable to the owners of the company	660.35	402.37
Earnings used in the calculation of basic earnings per share from continuing operations	660.35	402.37

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Weighted average number of equity shares for the purpose of basic earnings per share*	10,546,213	10,546,213
Weighted average number of equity shares for the purpose of diluted earnings per share*	11,172,213	10,546,213

During the year ended March 31, 2020, the Company has issued bonus shares in the proportion of 5:3 i.e. for every five (5) shares held, three (3) fully paid bonus equity shares of Rs. 10/- each were issued.

The bonus issue was approved by the shareholders of the Company in October 2019, through Postal Ballot/e-voting. Subsequently, the Company allotted 39,54,828 equity shares to shareholders who held equity shares as on the record date. The Bonus issue was transferred from Securities Premium to the Share capital.

EPS adjusted for the year prior to the bonus issue.

During the year ended March 31, 2023, the Company has issued 25,00,000 Share Warrant fully convertible to 25,00,000 Equity Share of Face Value Rs. 10 each.

32 - Information on related party transactions as required by Indian Accounting Standard 24 (Ind AS 24) on related party disclosures for the year ended March 31, 2023

- A Key Managerial Personnel ("KMP")
- | | |
|---------------------|--------------------------------|
| Mr. Atul Vasani | Chairman and Managing Director |
| Mrs. Jagruti Vasani | Whole Time Director |
| Mr. Dewansh Vasani | Executive Director |
| Mr. Hemant Pathak | Chief Executive Officer |
| Mr. Ratnesh Singh | Chief Financial Officer |
| Ms. Vishwa Mekhia | Company Secretary |
- B Relatives of Key Managerial Personnel ("KMP") with whom transactions have taken place during the year
- | | |
|---------------------|-----------------------------|
| Ms. Priyanka Vasani | Daughter of Mr. Atul Vasani |
| Ms. Vaishali Vasani | Sister of Mr. Atul Vasani |
| Mr. Ajay Vasani | Brother of Mr. Atul Vasani |
| Mr. Kevin Vasani | Son of Mr. Atul Vasani |
- C Entities over which Key Management Personnel and their relatives have significant influence and with whom transactions have taken place during the year ("Entities")
- | | |
|--------------------|------------------------------------|
| Arochem Industries | 25% partnership of Mr. Atul Vasani |
|--------------------|------------------------------------|



Details of Transactions with Related Parties

Sr No	Particulars	Year ended March 31, 2023			
		Key Management Personnel	Relatives of Key Management Personnel	Entities	Total
		a	b	c	
1	Remuneration	78.00 (73.84)	- -	- -	78.00 (73.84)
2	Salary paid	13.69 (12.44)	39.06 (37.48)	- -	52.75 (49.92)
3	Rent	17.40 (17.40)	5.40 (5.40)	- -	22.80 (22.80)
4	Advances given	- -	- -	- -	- -
5	Loan taken	415.50 (547.00)	- -	- -	415.50 (547.00)
6	Loan repaid	896.33 (1.84)	- -	- -	896.33 (1.84)
7	Material Purchased	- -	- -	- -	- -
8	Material Sold	0.07 (0.09)	- -	- -	0.07 (0.09)

Figures in the brackets are the comparative figures of the previous year

Sr No	Particulars	As at March 31, 2023			Total
		Key Managerial Personnel	Relatives of KMP	Other Related Parties	
1	Loan Payable	66.17	-	-	66.17
2	Rent Payable	5.24	1.50	-	6.74
3	Remuneration Payable	24.05	7.94	-	31.99
4	Advances given	-	-	-	-
5	Deposits given	7.00	2.50	-	9.50

Sr No	Particulars	As at March 31, 2022			Total
		Key Managerial Personnel	Relatives of KMP	Other Related Parties	
1	Loan Payable	547.00	-	-	547.00
2	Rent Payable	10.27	1.75	-	12.02
3	Remuneration Payable	36.64	7.16	-	43.81
4	Advances given	1.42	0.41	-	1.82
5	Deposits given	7.50	2.50	-	10.00

33A - Leases

Minimum lease rental payments

Sr no	Particulars	As at March 31, 2023	As at March 31, 2022
	Minimum lease rental payments		
1	Payable not later than one year	29.40	1.68
2	Payable later than one year and not later than five years	101.53	-
3	Payable later than five years	-	-

- The lease agreement provides for an option to Company to renew the lease period at the end of the non-cancellable period. There are no exceptional/restrictive covenants in the lease agreements.
- Further the company has entered into cancellable operating lease for office premises and godown. Tenures of leases generally vary from one year to five years. Terms of the lease include operating terms for renewal, terms of cancellation, etc.
- Lease payments in respect of the above leases are recognised in the Statement of Profit and Loss under the head Rent Expenses.

33B - Contingent Liabilities

As per the management of the company there are no contingent liabilities which are required to be disclosed in the notes to the financial statements.

34 - Key Ratios to disclosed as per additional Regulatory requirement of Schedule III to the Act

Sr no	Particulars	As at March 31, 2023	As at March 31, 2022	Variance in %
1	Current Ratio Current Ratio = Current Assets/Current Liabilities	2.27	1.47	54.00%
2	Debt-Equity Ratio Debt-Equity Ratio = Debt/Equity	0.34	0.79	-57.21%
3	Debt Service Coverage Ratio(DSCR) DSCR = Net Operating Income/Total Debt Services	3.45	2.23	54.57%
4	Return on Equity Ratio Return on Equity Ratio = Net Income/ Share Holder's Equity	0.16	0.15	6.90%
5	Inventory Turnover Ratio Inventory Turnover Ratio = Cost of Goods Sold/Average Inventory	29.72	104.34	-71.51%
6	Trade Receivable Turnover Ratio Trade Receivable Turnover Ratio = Net Credit Sales/Avg Account Receivable	1.24	1.21	2.49%
7	Trade payable Turnover Ratio Trade payable Turnover Ratio = Net Credit Purchases/Avg Account Payable	1.77	1.31	35.82%
8	Net Capital Turnover Ratio Net Capital Turnover Ratio = Total Sales/Shares holders Equity	1.77	2.94	-39.77%
9	Net Profit Ratio Net Profit Ratio = Net Profit/Sales	0.10	0.05	78.86%
10	Return on Capital Employed Return on Capital Employed = EBIT/(Shareholders Equity+Long Term Liabilities)	0.24	0.28	-14.45%



11	Return on Investment Return on Investment = Net Income/Cost of Investment*100	15.30	9.33	64.12%
----	---	-------	------	--------

35 – Additional disclosures required by schedule III (Amendments dated March 24, 2021) to the Companies Act, 2013

A. Relationship with struck off company

The Company has no transaction with the companies struck off under Companies Act, 2013 or Companies Act, 1956

B. Undisclosed income

The Company do not have any such transactions which are not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

C. Registration of Charges or Satisfaction with ROC

The company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

D. Utilisation of borrowings availed from banks

The borrowings obtained by the Company from banks have been applied for the purposes for which such loans were taken.

E. Borrowing secured against current assets

The Company has taken working capital borrowings from banks and financial institutions on the basis of security of current assets. The quarterly statement filed to the banks and financial institutions are in agreement with the books of accounts.

F. Details of benami property held

No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

G. Wilful defaulter

The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

H. Compliance with number of layers of companies

The Company has complied with the number of layers prescribed under the Companies Act, 2013.

I. Compliance with approved scheme(s) of arrangements

The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

J. Details of crypto currency or virtual currency

The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.

K. Title deeds of immovable properties held

The company holds all the title deeds of immovable properties in its name.

L. Utilisation of borrowed funds and share premium

a) No funds have been advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including

foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries).

b) The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

M. Valuation of PP&E, intangible asset and investment property

The Company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous year

- 36** The Previous year's figures have been regrouped / reclassified / rearranged / restated wherever necessary to match with the current year's classification / disclosures.

As per our report of even date attached

For Raman S. Shah & Associates

Chartered Accountants

Firm Registration No. 119891W

Sd/-

Santosh A. Sankhe

Partner

Membership No. 100976

For and on behalf of the Board

Vaishali Pharma Limited

CIN : L52310MH2008PLC181632

Sd/-

Atul Arvind Vasani

Chairman & Mg. Director
(DIN:02107085)

Sd/-

Jagruti Atul Vasani

Whole-time Director
(DIN:02107094)

Sd/-

Ratnesh Singh

Chief Financial Officer


Sd/-

Vishwa Mekhia

Company Secretary &
Compliance Officer

Mumbai, May 22, 2023

Mumbai, May 22, 2023



WAY AHEAD

Increased Global Presence

- Currently have presence in Asian, Middle East, African, CIS and Latin American Countries.
- Applied for 250 registrations in 35+ countries, out of which received 250+ approvals and remaining in process that will boost export operation.

Leveraging Market Skills And Relationships

- Continuous focus on leveraging market skills and relationship in organization.
- Training of Executives & Professionals
- Impart innovative and technical skills in people & to give importance

Market Expansion

- Nutraceuticals is newly introduced segment in Pharmaceuticals, and is one of fastest growing vertical in India & Other Countries. Nutraceuticals are entirely based on dietary supplements, Nutritional food additives and Immunity Boosters.
- To explore potential in Domestic market and plans to introduce many new molecules in 2022.
- Also, plans to expand by registering many more products in International market.



One Stop Destination For Healthy Healthcare Solutions



**QR CODE
SCAN HERE**

**706-709, 7TH FLOOR, ARAVALI BUSINESS CENTRE R.C.PATEL ROAD,
SODAWALA LANE, BORIVALI (WEST), MUMBAI – 400092, INDIA.**

investor@vaishalipharma.com - www.vaishalipharma.com